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Mechanisms and Regulation of Transforming Growth Factor Superfamily  
Mediated Gene Expression 
 
The TGF-β superfamily, including TGF-βs and BMPs, is critical for normal 
embryonic development, as well as disease progression, and is tightly regulated both 
within and out of cells. In vitro, TGF-β signaling mediated epithelial-mesenchymal 
transition (EMT) by activating mesenchymal genes and suppressing epithelial markers. 
We discovered that Wnt11 was directly regulated by the mediators of TGF-β signaling, 
Smad proteins. The induction of Wnt11 expression was critical for TGF-β associated 
activation of mesenchymal marker genes. Instead of modulating Smad proteins or 
activating canonical/β-Catenin signaling, Wnt11 controlled mesenchymal gene activation 
through JNK signaling. Our findings, for the first time, demonstrated the cooperativity 
among the TGF-β, Wnt11 and JNK signaling pathways in the context of EMT. Both 
TGF-β and BMP signaling are involved in renal fibrosis, but with opposite functions. 
TGF-β is a well known pro-fibrogenic factor, while BMP counteracts TGF-β to protect 
kidney from injuries. In our study, transgenic expression of kielin/chordin-like protein 
(KCP), an inhibitor of TGF-β and enhancer of BMP7, in renal epithelia attenuated the 
upregulation of mesenchymal genes in the injured kidney of unilateral ureteral 
obstruction (UUO) mouse model. These data demonstrated the importance of the balance 
of TGF-β and BMP signaling in the progression of renal fibrosis and provided a new 
potential therapeutic target. During kidney development, both BMP7 and Tle4, a 
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common corepressor, are present in metanepheric mesenchymal cells. However, their 
relationship is unknown. Here, we found that overexpression of Tle4 not only activated a 
BMP reporter, but also enhanced and sustained the upregulation of endogenous Id1 gene 
induced by BMP7. The effect of Tle4 on BMP signaling was through mediating Smad7 
protein, for Tle4 repressed Smad7 expression and overexpression of Smad7 totally 
abolished the activation of the BMP reporter by Tle4. Our study provides a new potential 






The transforming growth factor β (TGF-β) signaling pathway 
TGF-β Signal transduction 
Since the purification of its first ligand, TGF-β1, from human platelets in 1983 
(Assoian et al., 1983), much of research has focused on this superfamily and, more than 
30 ligands have been discovered in the human genome (Feng and Derynck, 2005; 
Massague, 2008). According to their sequence similarity nd biological effects, the TGF-
β superfamily can be divided into two distinct groups, the TGF-β/activin/nodal subfamily 
and bone morphogenetic proteins (BMPs)/anti-muellerian hormone (AMH)/growth and 
differentiation factors (GDFs) subfamily. The TGF-β signaling regulates a diverse set of 
cell processes. For example, TGF-βs caused cell cycle arrest in epithelial and 
hematopoietic cells and controlled mesenchymal cell pro iferation and differentiation, 
while BMPs were important for the differentiation of osteoblasts and the survival of renal 
mesenchymal cells (Massague, 1998; Patel and Dressle , 2005; Reddi, 1998). In fact, the 
TGF-β superfamily plays a key role throughout the whole embryonic development 
process and is involved in the formation of nearly l  organs. 
Although there are a number of ligands and several receptors, the general 
signaling transduction for TGF-β superfamily is relatively simple. In mammals, the 
binding of TGF-β ligand to its receptor, TGF-β receptor type II, leads to the recruitment 
and phosphorylation of TGF-β receptor type I (Derynck and Zhang, 2003). The activ ted 
TGFβRI is a serine/threonine kinase that transduces the signal through phosphorylating 
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receptor-activated Smad proteins (R-Smads), which are the main mediators for TGF-β 
signaling. Commonly, for TGF-βs, the R-Smads are Smad2 and 3, while for BMPs, they 
are Smad1, 5 and 8. The phosphorylated R-Smads usually form a heteromeric complex 
with a common partner, Smad4 (Co-Smads), and translocate into the nucleus. Normally, 
the Smad complex requires other transcriptional factors to activate or repress target gene 
expression (Itoh et al., 2000; Labbe et al., 2000; Sano et al., 1999). Besides R-Smads and 
Co-Smads, TGF-β signaling can induce the expression of a third group f Smad proteins, 
Smad 6 and 7 (Inhibitory Smads, I-Smads), which inhibits TGF-β signaling through 
competitive receptor binding and blocking the interaction between R-Smads and Co-
Smads (Hayashi et al., 1997; Imamura et al., 1997) (Figure 1-1). 
Since the TGF-β superfamily is widely involved in embryogenesis and 
subsequent organogenesis, it interacts with other signaling pathways, such as Wnt and 
Notch signaling. Also, because the TGF-β superfamily plays a critical role in a variety of 
biological process, it is highly regulated at different levels, from ligand releasing to 
mediator activation, and finally to transcriptional complex formation and target gene 
expression. In the following, we will discuss how TGF-β signaling is regulated and 
functions synergistically with other signaling pathways in a defined biological context. 
 
Regulation of receptor activation 
Despite the diversity of ligands in the TGF-β superfamily, they all share similar 
sequence and structure features. The active form of TGF-β cytokines is a homodimer of 
two 12.5 kd polypeptides stabilized by hydrophobic interactions and further joined by a 
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disulfide bond (Feng and Derynck, 2005; Shi and Massague, 2003). As for TGF-β 
isoforms (TGF-β1, 2, 3), its mature form is cleaved from homodimeric p oproteins (pro-
TGF-β) and interact with its N-terminal peptides, called the latency-associated proteins 
(LAPs), to form a small latent TGF-β complex (SL-TGF-β). When secreted from cells, 
the SL-TGF-β complex further interacts with the latent-TGF-β-binding protein (LTBP) 
through disulfide linkages to form the TGF-β large latent complex (LLC), which may be 
covalently anchored to the extracellular matrix (ECM) for storage (Annes et al., 2003; 
Hyytiainen et al., 2004). Whether the ligands from ther TGF-β subfamily undergo the 
same secreting process is not clear. 
Based on their structural and functional properties, the TGF-β receptor family is 
catalogued into two groups: type I receptors and type II receptors. Up to now, 7 type I 
and 5 type II recptors are dedicated to TGF-β signaling in the human genome (Manning 
et al., 2002) (Table 1-1).  Both types of the receptors are serine/threonine kinases, sharing 
a similar structure as an N-terminal extra-cellular ligand binding domain, a 
transmembrane region and a C-terminal serine/threonin  kinase domain (Shi and 
Massague, 2003). Compared to the type II receptor, the type I receptors have an extra 
domain between the transmembrane region and the kinase domain, termed GS domain 
(sequence as SGSGSG), which can be phosphorylated by the type II receptors and critical 
for the signaling activation (Souchelnytskyi et al., 1996; Wrana et al., 1994). As for the 
interaction between the ligands and receptors, there are two distinct modes represented 
separately by TGF-β/Activin subfamily and BMP subfamily. TGF-β and Activin showed 
a high affinity for the type II receptors and the type I receptor was recruited only after the 
ligand-type II receptor complex was formed (Massague, 1998). In contrast, from the 
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analysis of binding affinity, BMPs interacted with t e type I receptors first, then the type 
II receptors (Liu et al., 1995). No matter the sequence, the activation of the type I 
receptors and its interaction with Smad proteins requir d the phosphorylation of its GS 
domain by type II receptors (Feng and Derynck, 2005; Massague, 1998; Shi and 
Massague, 2003). 
The regulation of TGF-β receptor activation comprises two aspects: (1) 
controlling the access of TGF-β ligands to their receptors; (2) controlling the activation of 
type I receptors. Two classes of molecules with opposing function regulate the access of 
TGF-β ligands to their receptors (Massague and Chen, 2000; Shi and Massague, 2003). 
One class consists of a variety of soluble proteins that sequester TGF-β ligands and 
prevent their binding to the receptors. According to their targets, they can be further 
divided into three groups: (1) LAP, the small proteoglycan Decorin, the circulating 
protein α2-macroglobulin for TGF-βs; (2) Noggin, Chordin/SOG and DAN/Cerberus for 
BMPs; (3) follistatin for Activins and BMPs. The other class, membrane-anchored 
proteins, including betaglycan and endoglin may function as accessory receptors to 
enhance respective TGF-β signaling. 
As we discussed earlier, when the three TGF-β subfamily isoforms are secreted 
from cells, they are trapped by LAP and anchored to ECM by LTBP. The formation of 
this LLC prevents the mature TGF-β factors from binding to type II TGF-β receptor 
(Annes et al., 2003). Several factors or physiological condition changes can destroy this 
LLC and help releasing the active TGF-β ligands. First, a number of proteases, including 
plasmin and matrix metallopeptidase 2 and 9 (MMP2 and 9) can activate LLC through 
either proteolytic cleavage of LTBP (Taipale et al., 1994) or LAP (Lyons et al., 1988). 
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Second, thrombospondin-1 (TSP1) can physically interacts with LAP and induce a 
conformational change to release mature TGF-β ligands (Murphy-Ullrich and Poczatek, 
2000). Importantly, TSP1 null mice shared a similar phenotype with the TGF-β1 null 
mice (Crawford et al., 1998) and also TSP1 blocking peptides reduced the TGF-β 
activation in a rat fibrotic renal disease model (Daniel et al., 2004), suggesting that TSP1 
is responsible for a significant proportion of TGF-β activation in vivo. Third, it has been 
reported that TGF-β1 LAP was a ligand for the integrin αvβ6, and αvβ6-expressing cells 
induced spatially restricted activation of TGF-β1 (Munger et al., 1999). Furthermore, 
other integrins, such as αvβ8 and αvβ3 can function as a docking point for MMPs to 
activate TGF-β signaling (Mu et al., 2002; Rolli et al., 2003). Finally, some physiological  
changes in the microenvironment can destroy LLC, such as increasing reactive oxygen 
species (ROS) (Barcellos-Hoff et al., 1994) or decreasing pH (Lyons et al., 1988). 
Although the length and structure vary a lot among BMP antagonists, such as 
Noggin, Chordin/Sog and DAN family, they all share  common cysteine-rich region. For 
example, Noggin contains a carboxy-terminal cysteine-r ch (CR) domain, while Chordin 
contains four cysteine-rich repeats (Massague and Chen, 2000). The CR domains of the 
antagonists form homodimers to match the structure of BMP ligand homodimers. The 
crystal structure of the Noggin-BMP7 complex directly showed that Noggin inhibited 
BMP7 by blocking the surfaces that were required to in eract with the type I and type II 
BMP receptors (Groppe et al., 2002). Those antagonists are expressed during 
embryogenesis, and critical for the dosal-ventral ptterning and left-right asymmetry. 
Because those antagonists are important for the embryonic development, their expression 
was highly regulated. For example, in chicken, exprssion of Caronte, which belongs to 
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the DAN family, was induced by the sonic hedgehog signaling (Rodriguez Esteban et al., 
1999) and its diffusion was restricted by Lefty1(Yokouchi et al., 1999). Once the 
antagonist-BMP complex was formed, it could be furthe  activated through proteolytic 
cleavage by secreted metalloproteases, like Tolloid in Drosophila and zebrafish (Blader 
et al., 1997; Marques et al., 1997), Xolloid in Xenopus (Piccolo et al., 1997), and BMP1 
in human (Takahara et al., 1994). The effects of these metalloproteases on the BMP 
inactive complexes may be antagonist-dependent, since Xolloid in vivo specifically block 
the anti-BMP action of Chordin, but not Noggin or Follistatin (Blader et al., 1997). 
Interestingly, although most of the BMP antagonist shared the CR domain, not all 
proteins containing CR domain counteract BMP. Instead of blocking BMP signaling, the 
CR domain protein KCP and CV2 enhanced BMP-receptor interactions (Ikeya et al., 
2006; Lin et al., 2005). Thus, the interaction between the CR domain proteins and other 
proteins, such as ECM, may be also important for their function. 
Follistatin is a soluble secreted glycoprotein that could repress Activin signaling 
through direct ligand binding (de Winter et al., 1996). Besides Activin, it could also block 
BMP signaling through the similar mechanism (Iemura et l., 1998). 
Another class of proteins that could facilitate thedelivery of TGF-β ligands to the 
receptors are the membrane-anchored proteins, for which betaglycan is a good example. 
Betaglycan comprised a large extracellular domain for TGF-β ligand binding, a single-
pass transmembrane region, and a short intracellular domain associated with receptor 
trafficking (Bilandzic and Stenvers, 2011). It binds all three TGF-β isoforms with a 
preference for TGF-β2 (Esparza-Lopez et al., 2001), which could partially compensate 
the relatively low intrinsic affinity of TGF-β2 for type II TGF-β receptors (Cheifetz and 
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Massague, 1991). On the other hand, Betaglycan can also bind to inhibin and facilitates 
its access to Activin receptors, thus blocking Activin from its receptor (Lewis et al., 
2000). Recent work has also focused on function of the intracellular domain of 
Betaglycan. It revealed that the scaffolding protein β-arrestin2 interacted with Betaglycan 
and mediate its internalization with type II receptor through a clathrin-independent/lipid 
raft pathway, which repressed TGF-β signaling (Chen et al., 2003). Thus, the eventual 
outcome of these membrane-anchor proteins on TGF-β signaling may be highly 
dependent on cellular context. 
Besides the interaction control between the TGF-β ligands and their receptors, the 
signal transduction is also regulated on the type I r ceptor activation. As we mentioned 
above, the GS domain in type I TGF-β receptor is important for its activation. It has been 
reported that the immunophilin FKBP12 bound to thisregion, capping the type II TGF-β 
receptor phosphorylation sites and stabilizing the inactive conformation of type I receptor 
(Huse et al., 1999). The BMP and Activin receptor membrane bound inhibitor protein 
(BAMBI), a pseudoreceptor with a similar homodimerizat on interface of the type I 
receptor, can prevent the formation of receptor complexes, thus blocking BMP and 
Activin, as well as TGF-β signaling (Onichtchouk et al., 1999). 
 
Regulation of Smad proteins 
Smad proteins are the major mediators for the TGF-β signaling. Based on their 
structure and function, they can be divided into three groups: (1) receptor Smads (R-
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Smads, Smad 1, 2, 3, 5 and 8); (2) common Smad (Co-Smad, Smad4); (3) inhibitory 
Smad (I-Smad, Smad6 and 7). 
Generally, Smad1 and its close homologues Smad5 and Smad8 are substrates for 
the type I BMP receptors and respond to BMP signals, while Smad2 and 3 are the type I 
TGF-β and Activin receptors and respond to TGF-β and Activin signals (Massague, 
1998). In fact, the activation of a particular type of R-Smad is only associated with the 
specific type I receptors and has no relationship wth the ligands. For example, in 
endothelial cells, TGF-β ligands activated the Activin receptor-like kinase1 (ALK1) and 
cause the phosphorylation of Smad1, 5 and 8 (Goumans et al., 2002). The Co-Smad is not 
ligand restricted and does not interact with receptors. It can form a complex with all R-
Smad, but sometimes, its existence is dispensable. For example, the ubiquitious nuclear 
protein Transcriptional Intermediary Factor 1γ (TIF1γ) selectively bound phosphorylated 
Smad2 and 3 in competition with Smad4, so that TIF1γ and Smad4 mediated different 
biological effects of TGF-β in human hematopoietic stem/progenitor cells (He et al., 
2006). In spite of their different properties, the R-Smads and Co-Smads have similar 
structure. They all contain two conserved structural domains, the N-terminal Mad-
homolgy 1(MH1) domain and the C-termianl MH2 domain, separated by a more variable 
linker region (Ross and Hill, 2008; Shi and Massague, 2003). In addition, the R-Smads 
have a conserved SXS motif at their extreme C-termini, which is the site for receptor-
regulated phosphorylation. The MH1 domain of Co-Smads nd R-Smads, except for the 
most common isoform of Smad2, exhibits sequence-specific DNA binding ability (Shi et 
al., 1998). The MH1 domain is also involved in nuclear import (Xiao et al., 2000) and has 
an autoinhibitory effect on their MH2 domain (Hata et al., 1997). The MH2 domain 
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confers the interaction between Smads and receptors (L  et al., 1998) and is responsible 
for the formation of homomeric as well as heteromeric Smad complexes (Wu et al., 1997). 
Both the MH1 and MH2 domain can interact with a variety of transcriptional factors, 
activators and repressors, which largely increase the diversity of the biological effects of 
TGF-β signaling (Ross and Hill, 2008). The linker region is relative divergent among 
Smads, but it contain several phosphorylation sites that are important for the regulation. It 
also has a PY motif, which can be recognized by Smurf proteins for its ubiquitination 
(Izzi and Attisano, 2004). 
There are two types of I-Smads in vertebrate, Smad6 and Smad7. The MH1 
domain of I-Smads is less conserved to that of R-Smads or Co-Smads, however, their 
MH2 domain shows a similar amino acid sequence to other Smad proteins, but lack the 
C-terminal sites for receptor-mediated phosphorylation (Imamura et al., 1997; Nakao et 
al., 1997). Because of the similarity in the MH2 domain, I-Smads compete with R-Smads 
to interact with either type I receptors or Co-Smads, thus abolishing the transduction of 
TGF-β and BMP signaling. Generally, it is believed that Smad7 inhibits TGF-β/Activin 
and BMP signaling, whereas Smad6 works primarily on the BMP signaling (Hata et al., 
1998; Hayashi et al., 1997; Imamura et al., 1997; Nakao et al., 1997). More recently, 
another mechanism was found for the regulation of TGF-β signaling by I-Smads. It is 
reported that Smad7 could work as a connector to link Smurf ubiquitin ligases to the 
membrane receptors, resulting in the ubiquitination of the receptors and effectively 
blocking the signaling (Kavsak et al., 2000; Suzuki et al., 2002). 
Besides I-Smads, other proteins, such as Smad Anchor for Receptor Activation 
(SARA) and a cytoplasmic isoform of the promyelocyti  leukemia protein (cPML), also 
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mediate the interaction between R-Smads and type I receptors. SARA is a multidomain 
protein, containing a Smad-binding domain in the middle and a FYVE phospholipid-
binding domain, which is important for the localizat on of SARA but not its interaction 
with R-Smads or TGF-β receptors. SARA enhanced the interaction between Smad 
proteins and activated TGF-β receptors either on the plasma membrane or on the early
endosomes. Once the R-Smads were activated by the receptors, its interaction with 
SARA was weakened and the Smad-SARA-receptor complex was disassociated (Di 
Guglielmo et al., 2003; Tsukazaki et al., 1998). Meanwhile, SARA is also important for 
the receptor turnover and prevents its degradation mediated by the Smad7-Smurf 
complex (Di Guglielmo et al., 2003). The cPML is required for the association between 
Smad2/3 and SARA, and enhances the accumulation of SARA and TGF-β receptor in the 
early endosome through direct interaction with Smad2/3 and SARA (Lin et al., 2004). 
The function of cPML is interfered by a homeodomain protein, TG-interacting factor 
(TGIF), working in concert with c-Jun (Seo et al., 2006). Some modifications on the R-
Smad proteins can also regulate their interaction with receptors. It has been shown that 
the E3 ligase Itch promoted ubiquitination of Smad2 nd facilitated complex formation 
between the TGF-β receptors and Smad2 proteins (Bai et al., 2004). 
After R-Smad proteins are phosphorylated by the typ I receptors, they will form 
a complex with Co-Smads and translocate into the nucleus, where they either activate or 
repress target gene expression. This translocation pr cess is another regulation point for 
the TGF-β signaling transduction. The Smad complex can be imported into the nucleus 
either through importin-dependent mechanism or importin-independent mechanism. First, 
it has been shown that the MH2 domain of Smad proteins could interact directly with the 
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FG repeat regions on nucleoporins Nup153 and 214, thus helping transport the Smad 
complex into the nucleus independent of importin proteins (Xu et al., 2002). In addition, 
a conserved lysine-rich sequence in the MH1 domain of Smads could interact with 
importins (Kurisaki et al., 2001). However, the efficiency for the Smad translocation 
through the importin-dependent mechanism is lower than that through the importin-
independent mechanism (Xu et al., 2003). The modificat ons of R-Smads, especially in 
the linker region are critical for their translocation and transcriptional ability. It has been 
reported that the linker region of Smad1 could be phos horylated by the Erk MAP 
kinases, which were activated by epidermal growth factor (EGF), fibroblast growth factor 
(FGF) or stress. Phosphorylation prevented the nuclear accumulation of Smad1 and 
reduced its transcriptional activity (Kretzschmar et al., 1997; Pera et al., 2003; Sapkota et 
al., 2007). However, in contrary to Smad1, the phosrylation of Smad2 and 3 by MAP 
kinases or upstream MEK kinase enhanced their translocation and gene transactivation 
(Brown et al., 1999; de Caestecker et al., 1998; Funaba et al., 2002). Thus, the overall 
outcome of MAPK-related phosphorylation of R-Smad proteins is cellular context-
dependent and may be affected by other signaling pathways. Other kinases can also 
phosphorylate R-Smad proteins. It has been shown that G1 cyclin-dependent kinases 
Cdk2 and Cdk4 phosphorylated Smad3 at its linker region and negatively regulated the 
TGF-β mediated block of cell cycle progression (Matsuura et al., 2004). 
Calcium/Calmodulin-dependent kinase II (CamKII) phosphorylated Smad2, 3 and 4 in 
the MH1 and linker region, preventing Smad complex formation and nuclear 
translocation (Wicks et al., 2000). 
12 
 
The degradation of Smad proteins and their dephosphorylation are equally 
important in regulating the TGF-β pathway and terminate its signaling. Usually, the 
active Smad proteins are the targets of homologous t  E6-AP carboxyl terminus (HECT) 
domain E3 ligases and undergo the ubiquitin/proteasme mediated degradation pathway. 
The first HECT domain E3 ligase for Smad proteins was discovered in 1999 and called 
the HECT-domain Smad ubiquitination regulatory factors (Smurf) E3 ligase, Smurf1 
(Zhu et al., 1999), followed by the discovery of another member in this family, Smurf2 in 
2001 (Zhang et al., 2001). Smurf proteins interact with the PPXY motif of R-Smad 
proteins directly through their WW domains and it is believed that Smurf1 is responsible 
for the degradation of Smad1, while Smurf2 degrades both Smad1 and Smad2 (Zhang et 
al., 2001; Zhu et al., 1999). Besides Smurf1 and 2, the R-Smads are also degraded 
through other E3 ligase complex. For example, Smad3 physically interacted with 
Regulator of Cullins 1 (ROC1) and is degraded by Skp/cullin/F-box E3 ligase (SCF) 
complex (Fukuchi et al., 2001). Since Smad4 lacks a PPXY motif, its degradation by the 
HECT domain E3 ligases was mediated by the interaction with R-Smads (Moren et al., 
2005). The degradation of Smad4 could also be mediated through SCF complex (Wan et 
al., 2004). The mechanisms for the degradation of I-Smad proteins were similar to that of 
R-Smads. Furthermore, Smad7 proteins could function as an adapter to link Smurfs to the 
TGF-β receptors, thus facilitating the receptor degradation. This process may be further 
regulated by some other accessory proteins, such as WW domain-containing protein 1 
(WWP1) and ubiquitin-specific peptidase 15 (USP15) (Ebisawa et al., 2001; Eichhorn et 
al., 2012; Komuro et al., 2004). Additional modifications on Smad proteins also affect 
their degradation. The sumoylation of Smad4 by SUMO1/Ubc9 prolonged its half-life 
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because this modification competed with ubiquition (Li  et al., 2003a; Lin et al., 2003b). 
Smad7 could be acetylated by p300, thus preventing it from Smurf-mediated degradation 
(Goumans et al., 2002). This effect was counteracted by several class I, II and III histone 
deacetylases (HDAC) (Kume et al., 2007; Simonsson et al., 2005). Another way to 
terminate the TGF-β signaling is to remove the active phosphorylation of R-Smads at the 
C-terminal SXS motif. This could be achieved by pyruvate dehydrogenase phosphatase 
(PDP) and RNA polymerase II small C-terminal phosphatases (SCPs) for Smad1 (Chen 
et al., 2006; Knockaert et al., 2006), and Mg2+-dependent phosphatase PPM1A  for 
Smad2 and 3(Lin et al., 2006). 
 
Smad-dependent gene expression 
As transcriptional factors, R-Smads and Co-Smads, but not Smad2, have both 
DNA binding ability (except Smad2) through MH1 domain nd transactivation ability 
through the linker region (de Caestecker et al., 2000; Wang et al., 2005). However, the 
Smad complex still requires the association with oter transcription factors to regulate 
target genes more specifically and precisely. Both the MH1 and MH2 domains of Smad 
proteins can mediate the interaction with a long list of Smad interacting proteins, 
including the basic helix-loop-helix (bHLH) family, like E2F4/5(Chen et al., 2002) and 
Max (Grinberg and Kerppola, 2003), basic leucine zipper (bZIP) family, like c-Fos and c-
Jun (Zhang et al., 1998), Forkhead family, like FoxO 1, 3 and 4 (Seoane et al., 2004), 
Runx family, like Runx2 (Zhang et al., 2000), Zinc finger protein family, like Sp1(Feng 
et al., 2000) and YY1 (Lee et al., 2004) and mediators of other signaling pathway, like β-
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catenin (Zhou et al., 2012) and Notch intracellular domain (NICD) (Itoh et al., 2004). The 
interaction between Smad proteins and other transcriptional factors not only affects the 
number of target genes regulated by TGF-β signaling, but also functions as a platform, 
enabling the crosstalk between TGF-β and other signaling pathways. Furthermore, the 
Smad proteins also interact with coactivators or coepressors, which are equally 
important in mediating target gene expression. The coactivators, such as SMIF, Swift and 
Zeb1, enhanced Smad-dependent gene activation (Bai et al., 2002; Postigo et al., 2003; 
Shimizu et al., 2001), while the corepressors, such as TGIF, c-Myc and SnoN help Smads 
repress target genes (Feng et al., 2002; Luo, 2004; Wotton et al., 1999). On the chromatin 
level, the gene activation mediated by the Smad complex involved the recruitment of 
histone acetyltransferase CBP/p300 to the promoter sit s, either through its direct 
interaction with Smads or through the coactivators (de Caestecker et al., 2000; Feng et al., 
1998; Postigo, 2003). Histone methylation, especially histone 3 lysine 4 (H3K4) tri-
methylation, may be also involed in Smad-dependent g e activation (Patel et al., 2007; 
Shimizu et al., 2001). On the other hand, the recruitment of C-terminal-binding protein 1 
(CtBP) repressor and histone deacetylases (HDACs) is critical for Smad-mediated gene 
repression (Akiyoshi et al., 1999; Izutsu et al., 2001; Wotton et al., 1999). Besides 
regulating the histone modification and chromatin remodeling, Smad proteins could 
further repress gene expression by sequestering the transcriptional factor from its 
coactivators. For example, Smad3 could bind with MEF2, blocking its interaction with 
the coactivator GRIP1, thus inhibiting myogenic differentiation (Liu et al., 2004). 
 
Smad-independent TGF-β signaling transduction 
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Many other signaling pathways may participate in TGF-β mediated biological 
responses. First, TGF-β can activate the MAPK pathway. In monkey derived COS7 cells, 
overexpressed human X-chromosome-linked inhibitor of ap ptosis protein (XIAP) linked 
TAB1 to type I BMP receptor and this interaction may be necessary for the activation of 
TAB1-associated protein, TAK1, which belongs to the MAP kinase kinase kinase 
(MAPKKK) family (Yamaguchi et al., 1999). However, evidence for the direct 
interaction between the endogenous XIAP, TAB-TAK complex and type I BMP receptor, 
is still missing. Similarly, in mouse mammary epithelial (NMuMG) cells or human 
fibrosarcoma cells, p38 MAPK or JNK signaling was activated by TGF-β (Hocevar et al., 
1999; Yu et al., 2002), but the mechanisms involving this activation were poorly 
characterized. Besides MAPK cascades, TGF-β could also activated small GTPases, like 
RhoA and Cdc42, which are important for TGF-β mediated epithelial-mesenchymal 
transition in epithelial cells and re-organization f stress fibers in human prostate 
carcinoma cells (Bhowmick et al., 2001; Edlund et al., 2002). However, like the MAPK 
pathways, little evidence showed that the activation of these small GTPases is through 
TGF-β receptors, and not through secondary effects. Finally, it has been shown that upon 
the ligand-dependent activation, type I TGF-β receptor physically bound to Bα, a WD-40 
repeat subunit of phosphatase 2A (PP2A), which in tur dephosphorylated and inactivate 
p70(s6k), inducing cell cycle G1 arrest (Griswold-Prenner et al., 1998; Petritsch et al., 







Epithelial-Mesenchymal Transition (EMT) 
The epithelial mesenchymal transition (EMT) is a common biological process, 
which occurs when epithelial cells lose their polarized morphology and tight junctions 
and acquire mesenchymal properties, such as enhanced migratory capacity, elevated 
resistance to apoptosis and increased production of extracellular matrix. In fact, EMT 
occurs throughout development, from embryogenesis to the organ formation, and is 
involved in a variety of diseases. Based on the functio al distinctions, EMT can be 
further divided into three types: (1) EMT that occurs during normal development 
processes, such as implantation, embryo formation and organ development. The 
mesenchymal cells derived from this type of EMT can also undergo a mesenchymal-
epithelial transition (MET) to generate secondary epithelia; (2) EMT that is associated 
with wound healing, tissue regeneration and organ fibrosis. This type of EMT is 
frequently triggered by ongoing inflammation, however, its real existence in vivo remains 
controversial; (3) EMT that is related to cancer progression, especially the metastasis of 
carcinoma cells. One prominent characteristic for this ype of EMT is its heterogeneity 
with some cells keeping most of epithelial traits and acquiring some mesenchymal 
properties, while others shedding all vestiges of their epithelial origin and cecoming fully 







Type I EMT 
Type I EMT is involved in several stages during development. First, during 
mouse gastrulation, epiblast cells at the primitive streak, which is a transient structure 
forming along the posterior midline of the embryo, undergo the EMT (also known as 
epiblast-mesoderm transition) and then ingress between the epiblast and visceral 
endoderm to participate in the formation of either the mesoderm or the definitive 
endodermal germ layers (Ciruna and Rossant, 2001). Another EMT occurs in neural-crest 
cells, which is a transient population of cells at the boundary between epidermal and 
neural territories, to promote migration, thus giving rise to many different derivatives 
(Thiery and Sleeman, 2006). Subsequently, EMT is involved in the organ formation. For 
example, EMT is necessary for the regression of the Mullerian duct in male reproductive 
tracts (Zhan et al., 2006). Also, endothelial cells from the atrioventricular canal undergo 
EMT to invade the cardiac jelly and form the endocardial cushion, which will later 
assemble into the atrio-ventricular valvulo-septal complex (Nakajima et al., 2000). 
 
Type II EMT 
Type II EMT was thought to occur in the fibrosis of several organs, such as 
kidney, liver, lung and heart (Iwano et al., 2002; Kim et al., 2006; Zeisberg et al., 2007a; 
Zeisberg et al., 2007b). Here, we will take renal iterstitial fibrosis as an example. Renal 
interstitial fibrosis is a common pathology in most chronic and progressive kidney 
diseases and characterized by inflammatory cell infi tration, fibroblast activation and 
18 
 
expansion, extracellular matrix deposition and tubular atrophy (Liu, 2011). The 
increasing number of fibroblasts may come from various resources. First, they can 
originate from the local resident interstitial cells (Humphreys et al., 2010; Lin et al., 
2008). Another source is the recruitment of circulating fibrocytes, which are a subset of 
bone marrow-derived, circulating monocytes capable of producing collagen I. However, 
because specific markers for this group of cells are l cking, their contribution for renal 
fibrosis remains controversial (Niedermeier et al.,2009; Roufosse et al., 2006). Lastly, 
fibroblasts may come from epithelial cells through EMT. 
The initial evidence supporting EMT involved in renal fibrosis in vivo came in 
2002 (Iwano et al., 2002). Through a lineage tracing experiment, the authors showed that 
the epithelial cells expressed the fibroblast marker, fibroblast specific protein 1 (FSP1) 
and synthesize collagen I. Since then, more and more research tried to demonstrate the 
existence of EMT in renal fibrosis. These studies can be categorized into two groups. The 
first group of studies showed the up-regulation of mesenchymal markers in renal 
epithelial cells in injured kidney, such as α-smooth muscle actin (αSMA) (Yang and Liu, 
2001), plasminogen activator inhibitor 1 (PAI1) (He et al., 2010), vimentin (Rastaldi et 
al., 2002), and Snail1 (Yoshino et al., 2007). The second group revealed that genetic or 
pharmaceutical manipulation of EMT related transcriptional factors or signaling 
pathways enhanced or attenuated renal fibrosis. For example, mice lacking Smad3, the 
key mediator for TGF-β signaling pathway were protected against tubulointerstitial 
fibrosis by blocking EMT (Sato et al., 2003). A similar experiment showed that systemic 
administration of recombinant human BMP7 led to repair of the damage in renal tubular 
epithelial cells through counteract the EMT effects induced by endogenous TGF-β1 
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(Zeisberg et al., 2003). Furthermore, ectopic activtion of Snail1 in kidney was sufficient 
to induce renal fibrosis (Boutet et al., 2006). Besid  these in vivo results, more in vitro 
studies proved the existence of EMT in cell culture (Cheng and Lovett, 2003; Huang et 
al., 2009; Qi et al., 2005; Slattery et al., 2005). 
However, improved lineage tracing results published in recent years argued 
strongly against the EMT model in renal fibrosis. In one study, the authors separately 
used the Six2 promoter to mark all tubular cells derived from the cap mesenchyme and 
the Hoxb7 promoter to mark all tubular cells from the ureteral bud to label the tubular 
cells, but failed to find the fibroblasts in peritubular interstitium with these positive 
genetic markers (Humphreys et al., 2010). Another study used Pax8-rtTA mice to 
simultaneously induce TGF-β1 and label all proximal, distal and collecting duct tubular 
cells (Koesters et al., 2010; Traykova-Brauch et al., 2008). Even under these favorable 
conditions with overexpressing TGF-β1, labeled epithelial cells were not found in the 
interstitial fibrosis region, but instead, underwent the autophagy. If there is EMT in 
fibrosis, the transiting epithelial cells must migrate through the tubular basement 
membrane (TBM) into the interstitial region, where they proliferate and deposit ECM. 
However, up to now, no transmission electron microsopy data are provided to show that 
even a single cell is crossing the TBM. Furthermore, although the TBM may become 
collapsed and highly folded, its integrity is preserved (Kriz et al., 2011). 
Based on these two contradictory facts, a concept, called “partial EMTs”, was 
proposed (Kalluri and Weinberg, 2009; Liu, 2011). In this partial EMT, epithelial cells 
only change one or two phenotypic markers, while maintaining other epithelial 
characteristics. Although the current results do not support a typical EMT process in renal 
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fibrosis, the upregulation of mesenchymal markers in epithelial cells may still be 
biological important. For example, it has been repoted that Snail and Zeb proteins could 
directly repress the expression of E-Cadherin, which is a critical marker for epithelial 
cells (Cano et al., 2000; van Grunsven et al., 2003). This may be significant for the 
apoptosis or autophagy of epithelial cells, and eventually the tubular atrophy in renal 
fibrosis. Also, the metalloproteinases, such as MMP2 and MMP9, secreted from 
epithelial cells could be critical for the remodeling of ECM in interstitium, thus activating 
quiesence fibroblasts. So the precise function of upregulated mesenchymal markers in 
epithelial cells and the paracrine effects of those cells on adjacent cells still require 
further studies. 
 
Type III EMT 
The EMT program confers upon cancer epithelial cells the ability to detach from 
each other and invade adjacent cell layers or migrate to distant locations (Yang and 
Weinberg, 2008). In fact, EMT was found in nearly all types of carcinoma (Thiery et al., 
2009). For example, in breast carcinoma, a mouse lineage tracing study proved that EMT 
occurred specifically in Myc-initiated tumors (Trimboli et al., 2008). The EMT 
biomarkers, such as Snail, are associated with histological grades and the metaplastic 
subtype of breast carcinoma (Blanco et al., 2002; Lien et al., 2007). Similarly, based on 
an analysis of 123 primary human hepatocellular carcinoma (HCC) samples, the 
overexpression of Snail and Twist was correlated with a worse prognosis (Yang et al., 
2009). This analysis was supported by the in vitro study, showing that overexpression of 
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Snail in an established HCC cell line HepG2 caused its dedifferentiation into 
fibroblastoid featured with increasing invasion activity (Miyoshi et al., 2004). Recent 
studies revealed that EMT not only increases the mobility of transformed cells, but also 
confers upon them the stemness with enhanced ability to form mammospheres and 
tumorigenesis (Mani et al., 2008; Santisteban et al., 2009). These results suggested that 
besides increasing the tumor invasion, EMT may be involved in the initiation of breast 
carcinoma by increasing the tumor cell pool. Interestingly, when migratory tumor cells 
settle at distant sites, they no longer exhibit the m senchymal phenotypes ascribed to 
metastasizing carcinoma cells (Kalluri and Weinberg, 2009). This observation indicates 
that the microenvironment surrounding the tumor cells is critical in maintaining their 
transforming state (Scheel et al., 2011). 
 
Signaling pathways associated with type II EMT 
Although EMT can be divided into three types and occur in different situations, 
its key events at the molecular level are the same, downregulation of epithelial markers, 
such as E-Cadherin, and upregulation of mesenchymal genes, such as Snail, Zeb, Pai and 
Twist. The signaling pathways involved in three types of EMT are also similar. So here, 
we will mainly focus on the signaling pathways associated with type II EMT in the 
context of renal fibrosis. 
TGF-β signaling 
TGF-β signaling pathway is the most well studied pathway for EMT. In vitro 
study suggested that TGF-β could activate mesenchymal marker genes, such as αSMA 
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and Snail, as well as repress epithelial markers, like E-Cadherin and Occuldin in at least 
two different renal epithelial cell lines, MDCK from dog and HKC8 from human (Medici 
et al., 2006; Yang and Liu, 2001). Snail1 could furthe  form a complex with Smad3 and 4, 
which was targeted to the promoters of CAR, a tight-junction protein, and E-cadherin to 
repress their expression (Vincent et al., 2009). In vivo, the severity of renal 
histopathology has been significantly lessened in experimental glomerular nephritis 
models by treating animals with antibodies against TGF-β ligands (Border et al., 1990) or 
the type II TGF-β receptors (Kasuga et al., 2001). Tubular epithelial cells are the main 
targets for TGF-β in renal fibrosis, since in the unilateral ureteral obstruction (UUO) 
mouse model, expression of both TGF-β and its type I receptor increased rapidly and 
specifically in renal tubular epithelia (Yang and Liu, 2001). BMP7 signaling pathway 
counteracts the effects of TGF-β in inducing EMT. As we mentioned above, systemic 
administration of recombinant human BMP7 led to repair of severely damaged renal 
tubular epithelial cells (Zeisberg et al., 2003). In vitro, BMP7 not only restored the 
expression of epithelial markers, repressed by TGF-β in renal epithelial cells, such as E-
Cadherin and ZO-1 (Zeisberg et al., 2003), but alsocaused the mesenchymal-epithelial 
transition (MET) in adult renal fibroblasts, characterized by cell condensation, decreased 
motility and increased expressing E-Cadherin (Zeisberg et al., 2005). At the molecular 
level, BMP7 prevented TGF-β mediated loss of the transcriptional repressor SnoN and 
limited Smad3 DNA binding without affecting its phosphorylation or stability (Luo et al., 
2010). 
Canonical Wnt/β-Catenin signaling 
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The canonical Wnt signaling pathway functions by preventing the degradation of 
cytoplasmical β-Catenin by GSK3β/Axin/APC complex. The accumulated β-Catenin 
translocates into the nucleus, where it interacts wi h TCF/LEF proteins to regulate gene 
expression (MacDonald et al., 2009). In the UUO models in vivo, several Wnt ligands 
were up-regulated, such as Wnt1, Wnt4 and Wnt11 (He et al., 2009; Surendran et al., 
2002), and β-Catenin predominantly accumulated in tubular epithelia. Blocking of Wnt 
signaling by administrating its inhibitor, such as Dkk1 and Sfrp4, attenuated the renal 
injury, reduced the upregulation of mesenchymal genes and maintained the expression of 
epithelial markers. (He et al., 2009; Surendran et al., 2005). In vitro, it has been shown 
that β-Catenin mediated the activation of mesenchymal genes, such as Pai1, αSMA and 
Snail1, alone or together with Smad proteins (Hao et al., 2011; He et al., 2010; Zhou et 
al., 2012). Besides the Wnt ligands, β-Catenin may also accumulate from the collapse of 
cell-cell contacts during EMT induced by TGF-β. In this case, β-Catenin seems to work 
downstream of TGF-β signaling to regulate mesenchymal gene expression (Zheng et al., 
2009).  It is not clear whether Wnt ligands are also up-regulated in the process and 
facilitate β-Catenin accumulation. However, under most cases, Wnt and TGF-β signaling 
function cooperatively in mediating EMT and renal fibrosis. 
Notch signaling 
The notch signaling pathway is comprised of four receptors and two ligands, 
Delta and Jagged (Jag) (Guo and Wang, 2009). When liga ds from the signal-giving cells 
bind to receptors on the signal-receiving cells, Notch intracellular domain (NICD) will be 
released from the plasma membrane through a series of proteolytic cleavages on the 
Notch receptors. NICD will then translocate into nucle s and regulate target gene 
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expression. In UUO models, the Notch ligand, Jagged1, was up-regulated in the distal 
tubular epithelial cells in injured kidneys. Along with this, the mediator of Notch 
signaling, NICD also accumulated in tubular epithelial cells. The mouse results were 
confirmed by human biopsy with diabetic kidney disea s (Bielesz et al., 2010; Morrissey 
et al., 2002). Pharmaceutical block of Notch signaling by γ-secretase inhibitor 
ameliorated tubulointerstitial fibrosis, while enhaced expression of NICD driven by the 
Pax8 promoter, in tubular epithelial cells caused activation of mesenchymal markers and 
renal fibrosis (Morrissey et al., 2002). In vitro, it is not clear whether Notch signaling 
alone can induce EMT in renal epithelial cells. However, Notch signaling could be 
activated by TGF-β signaling to promote EMT in either rat or human tubular epithelial 
cells (Bielesz et al., 2010; Nyhan et al., 2010). In the type III EMT, Notch signaling 
promoted EMT by suppressing expression of the microRNA-200 (miR-200) through 
GATA-binding (Gata) factors in lung adenocarcinoma (Yang et al., 2011) or Zeb1 in 
pancreatic cancer cells (Brabletz et al., 2011). Whether this mechanism is still applicable 
to the type II EMT is unknown. 
Integrin-associated signaling 
Integrins consist of an α-subunit and a β-subunit, which are transmembrane 
receptors, that binds to the ECM outside the cell and interacts with cytoskeleton inside 
the cell. Integrins could pass signaling through two pathways. First, since they connect 
the ECM and cytoskeleton, it could function as a bridge to physically transduce 
mechanical strength from cells to the microenvironme t or in reverse. Second, their β-
subunits interact with integrin-linked kinase (ILK), an intracellular serine/threonine 
protein kinase and activate signaling through phosprylation cascades. It has been 
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reported that both αvβ6 integrin and ILK were upregulated in renal epithel a in mouse 
UUO models or human biopsies with glomerulonephritis or other kidney diseases (Hahm 
et al., 2007; Li et al., 2003). The severity of renal fibrosis was reduced with application of 
antibody against αvβ6 integrin (Hahm et al., 2007). In vitro, overexpression of ILK in 
human kidney proximal epithelial cells suppressed expr ssion of E-Cadherin, and 
induced fibronectin and MMP2 expression (Li et al.,2003). Normally, the function of 
αvβ6 integrin in mediating EMT or renal fibrosis is associated with TGF-β signaling. First, 
αvβ6 integrin could stimulate TGF-β signaling through facilitating the release of active 
form of TGF-β ligands from their latent complex. Consistent with this fact, both active 
TGF-β protein expression and Smad2 phosphorylation were less in UUO kidney with β6 
subunit knockdown (Ma et al., 2003). Second, inhibition of ILK expression by hepatocyte 
growth factor (HGF) blocked TGF-β induced EMT and attenuate renal fibrosis (Li et al., 
2003). Thus, it seems that TGF-β and αvβ6 integrins work in a positive feedback mode to 
regulate EMT and renal fibrosis. In addition, another subunit of integrin, α3, was 
important for the phosphorylation of β-catenin at tyrosine residue 654 to enhance the 
interaction between β-catenin and Smad2 and initiate EMT in lung fibrosis (Kim et al., 
2009). 
Platelet derived growth factors (PDGFs) signaling 
PDGF is a major mitogenic factor, whose receptors are tyrosine kinases. Upon 
stimulation, PDGFR transduce the signaling through activating several downstream 
molecules, such as Stat proteins, phosphatidylinositol-3 kinase (PI3K) and Ras (Floege et 
al., 2008). It has been shown that PDGF-C was upreglated at sites of interstitial fibrosis 
in human and rat kidneys (Eitner et al., 2008). Blocking PDGF-C or PDGF-D by 
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neutralizing antibodies reduced tubulointerstitial d mage and fibrosis (Eitner et al., 2008; 
Ostendorf et al., 2006). The increase in PDGF-C expression was due, in large part, to 
infiltrating macrophages (Eitner et al., 2008). Although PDGF antibodies help preserve 
cortical expression of E-Cadherin and reduce expression of vimentin and α-SMA in vivo, 
the direct effects of PDGF signaling on renal epithel al cells are unknown. Some studies 
have focused on exploring the function of PDGF in type III EMT. It was found that 
mammalian target of rapamycin (mTor) and nuclear factor-κB (NF-κB) were activated 
upon PDGF-D overexpression in human prostate cancer cell line PC3 cells (Kong et al., 
2008). Another study revealed that PDGF treatment promotes β-catenin nuclear 
translocation through disrupting GSK-3β/Axin/APC degradation complex by p68 RNA 
helicase in a Wnt-independent manner (Yang et al., 2006). These studies may provide 
hints for researches exploring mechanisms of PDGF signaling on renal fibrosis. 
Hypoxia associated signaling 
Renal hypoxia, instead of being a consequence of renal fibrosis, may serve as an 
inducer for fibrogenic process (Manotham et al., 2004). Hypoxia inducible factor 1 
(HIF1), the stability of which is based on the oxygen concentration, is the main regulator 
for the cellular responses to hypoxia. It has been r ported that hypoxia induces 
morphological and gene expression profile change in proximal tubular epithelial cells 
partial through HIF1 (Higgins et al., 2007). Also, HIF1 accumulation was found in 
tubular epithelial cells in both mouse UUO models and human renal biopsies from 
patients with chronic kidney disease. HIF1 deletion r lysyl oxidases inhibition 
attenuated fibrosis in UUO kidneys (Higgins et al.,2007). On the molecular level, the 
mesenchymal marker genes, Twist and Snail are the direct targets of HIF1α (Luo et al., 
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2011; Yang et al., 2008). HIF1α mediated activation of mesenchymal genes required th  
recruitment of histone methyltransferase (HMT) by histone deacetylase 3 (HDAC3) and 
WDR5 (Wu et al., 2011). 
 
Summary 
TGF-β superfamily, which includes TGF-βs and BMPs, is critical for normal 
development, as well as disease progression, and is tightly regulated both within and out 
of cells. In vitro, TGF-β induced the transition of renal epithelial cells into fibroblast-like 
mesenchymal cells by activating mesenchymal genes ad repressing epithelial markers. 
Although the existence of this EMT in renal fibrosis is controversial, the upregulation of 
mesenchymal genes in renal epithelia may be critical for the initiation and progression of 
renal fibrosis. Considering the obvious and consistent phenotype change, the in vitro 
EMT model is also a good platform to study the mechanisms of TGF-β signaling in target 
gene activation, and crosstalk among different signal ng pathways. Outside the cells, the 
regulation of TGF-β signaling could be achieved by sequestration or enhanced delivery of 
ligands to receptors. Inside the cells, TGF-β signaling could be regulated at different 
stages, such as the activation of R-Smads, the interaction between R-Smad and Smad4, 
and the access of Smad containing transcriptional complex to target genes. 
In this dissertation, we will discuss both mechanisms and regulations of TGF-β 
superfamily mediated gene expression. In Chapter II, our results demonstrated that TGF-
β activated Wnt11 was important for the upregulation of mesenchymal genes in renal 
epithelial cells. Furthermore, Wnt11 mediated TGF-β induced mesenchymal gene 
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expression through JNK signaling. In Chapter III, we showed that specific 
overexpression of KCP, a secreted cysteine rich protein, in renal epithelia attenuated the 
upregulation of some mesenchymal marker genes in injured kidneys of unilateral ureteric 
obstruction (UUO) model, by repressing TGF-β signaling and sustaining BMP signaling. 
In Chapter IV, our study revealed that Tle4 overexpssion not only activated a BMP 
reporter, but also enhanced and sustained the upregulation of endogenous Id1 gene 
induced by BMP7. Furthermore, the effect of Tle4 on the BMP reporter was mediated by 
Smad7. Tle4 suppressed Smad7 expression and overexpr ssion of Smad7 totally 
abolished the activation of Tle4 on the BMP reporter. Taken together, this dissertation 
dissected the mechanism of TGF-β to activate target gene expression in renal epithelial 
cells and also studied the regulation of TGF-β and BMP signaling, extracellularly by 













Figure 1-1. Schematic diagram of TGF-β superfamily signaling from cell membrane 
to the nucleus. The arrows indicate signal flow and phosphate groups are represented by 
red dots. R-Smad, receptor-Smad; Co-Smad, common-Smad; I-Smad, inhibitory-Smad; 









Table 1-1. Combinational interactions of Type II and Type I TGF-β receptors in 
vertebrates. 
Type II     Type I     R-Smad 
TβRII ALK-5 (TβRI) Smad2, Smad3 
ALK-1 Smad1, Smad5 
ALK-2 
BMPRII, BMPRIIB ALK-2 (ActRI) Smad1, Smad5, Smad8 
ALK-3 (BMPRIA) 
ALK-6 (BMPRIB) 
ActRII, ActRIIB ALK-4 (ActRIB) Smad2 
AlK-7 
AMHR ALK-2 Smad1, Smad5 
ALK-3 
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Activation of Wnt11 by TGF-β Drives Mesenchymal Gene Expression through Non-
Canonical Wnt Signaling in Renal Epithelial Cells 
 
Abstract 
Transforming growth factor β (TGF-β) promotes renal interstitial fibrosis n vivo 
and the expression of mesenchymal genes i  vitro, however most of its direct targets in 
epithelial cells are still elusive.  In a screen for genes directly activated by TGF-β, we 
found that components of the Wnt signaling pathway, especially Wnt11, were targets of 
activation by TGF-β and Smad3 in primary renal epithelial cells (PRECs).  In gain and 
loss of function experiments, Wnt11 mediates the actions of TGF-β through enhanced 
activation of mesenchymal marker genes, such as Zeb1, Snail1, Pai1, and αSMA, without 
affecting Smad3 phosphorylation. Inhibition of Wnt11 by receptor knockdown or 
treatment with Wnt inhibitors limited the effects of TGF-β on gene expression. We found 
no evidence that Wnt11 activated the canonical Wnt signaling pathway in renal epithelial 
cells, rather the function of Wnt11 was mediated by the c-Jun N-terminal kinase (JNK). 
Our findings demonstrate cooperativity among the TGF-β, Wnt11 and JNK signaling 
pathways and suggest new targets for anti-fibrotic therapy in renal tissue.    
Introduction 
Renal interstitial fibrosis is a common pathology in most chronic and progressive 
kidney diseases (Liu, 2010).  The function of the profibrotic cytokine TGF-β in the 
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initiation and progression of fibrosis has been intensively studied in the kidney and other 
tissues (Bottinger and Bitzer, 2002; Yang and Liu, 2001; Zeisberg et al., 2007).  In almost 
all animal models examined, increased renal fibrosis correlates with increased expression 
of TGF-β ligands.  Renal fibrosis is observed upon overexprssion of TGF-β or 
application of recombinant TGF-β in mice, whereas inhibition of the TGF-β pathway can 
alleviate the severity of progressive renal fibrosis (Border et al., 1990; Kopp et al., 1996; 
Ledbetter et al., 2000).   
In mammals, the binding of TGF-β ligand to its receptor, TGF-β receptor type II, 
leads to the recruitment and phosphorylation of TGF-β receptor type I (Feng and Derynck, 
2005). The activated TGFβRI is a serine/threonine kinase that transduces the signal 
through phosphorylating receptor-activated Smad2 and Smad3.  Phosphorylated Smad2/3 
form a heteromeric complex with a common partner, Smad4, and translocate to the 
nucleus.  Normally, the Smad complex requires other transcriptional factors to activate or 
repress target gene expression (Labbe et al., 2000; Sano et al., 1999).  Both Smad2 and 
Smad3 are activated in TGF-β signaling pathway, but their targets and functions are 
distinct (Meng et al., 2010; Phanish et al., 2006).  Genetic experiments point to a critical 
role for Smad3 in promoting TGF-β mediated renal fibrosis.  Despite the evidence 
pointing to TGF-β as a profibrotic agent, its gene targets and detailed mechanisms that 
promote fibrosis are still not well characterized.  
Renal tubular epithelial cells are target cells for TGF-β in kidney fibrosis (Yang 
and Liu, 2001). In the unilateral ureteral obstruction (UUO) mouse model, expression of 
both TGF-β and its type I receptor increased rapidly and specifically in renal tubular 
epithelia.  In vitro, epithelial cells treated with TGF-β lost expression of epithelial markers 
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and assume a more mesenchymal phenotype. This epithelial-to-mesenchymal transition 
(EMT) was thought to occur in animal models of inters itial fibrosis and was an attractive 
model to explain the increased number of fibroblasts and the loss of epithelial tubular 
integrity (Iwano et al., 2002). In chapter I, we have thoroughly discussed different types of 
EMT and the controversy of the existence of type II EMT in renal fibrosis. Regardless of 
whether EMT occurs in vivo, the direct impact of TGF-β on the renal epithelial cells 
appears critical for initiation and progression of fibrosis. Meanwhile, the in vitro cell 
studies were a good model to study the function of different signaling pathways in cell fate 
determination, and provide valuable insights into  vivo disease models.   
The Wnt signaling pathways have also been linked to TGF-β and to EMT during 
normal development and diseases.  There are 19 Wnt liga ds in the mouse and human 
genomes. These different Wnt ligands can signal through the canonical, β-catenin 
dependent pathway, or the non-canonical, β-catenin independent pathway.  In the 
canonical pathway, activated Wnt signaling prevents the degradation of β-catenin by the 
GSK3β/Axin/APC complex.  The accumulating β-catenin then interacts with TCF/LEF 
proteins to regulate gene expression (MacDonald et al., 2009).  One branch of the non-
canonical Wnt pathway involves the calcium influx and further activation of 
Ca2+/calmodulin-dependent kinase II (CamKII) and protein kinase C (PKC) (Kuhl et al., 
2000; Veeman et al., 2003).  Another branch of the non-canonical pathway transduces its 
signal by activating the c-Jun N-terminal kinase (JNK) pathway either through small 
GTPase or other mechanisms (Veeman et al., 2003).  
Although the Wnt signaling pathways were shown to function in EMT in vitro and 
in fibrosis in vivo (He et al., 2009; Scheel et al., 2011) , the relationships with the 
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profibrotic cytokine TGF-β are not well defined.  A limited number of studies addressing 
the cross-talk of TGF-β and Wnt signaling pathway converged on the β-catenin, as TGF-β 
could stabilize β-catenin by inhibiting its GSK3β-dependent degradation through p38 
MAPK and Akt (Hwang et al., 2009; Liu, 2010; Masszi et al., 2004).  Also β-catenin 
could physically interact with Smad proteins to regulate target gene expression (Kim et al., 
2009; Zhang et al., 2010; Zhou et al., 2012b).  Yet, little is known about the function of 
non-canonical Wnt signaling pathway in fibrosis and its relation to TGF-β.   
In this chapter, we defined the targets of TGF-β in renal epithelial cells in vitro by 
global gene expression analysis.  We showed that components of the Wnt signaling 
pathways were activated by TGF-β.   Among these, the non-canonical signaling protein 
Wnt11 was directly regulated by TGF-β through Smad3 in both primary and immortalized 
renal epithelial cells.  Wnt11 enhanced the effects of TGF-β and was necessary for 
maximal activation of mesenchymal gene such as Zeb1, Snail1, Pai1 and the 
myofibroblast marker αSMA.  Wnt11 did not enhance P-Smad3 nor activate the canonical 
Wnt signaling pathway, rather it appeared to increase mesenchymal gene expression 
through the non-canonical JNK pathway.  These results pointed to a critical role for non-
canonical Wnt signaling in TGF-β mediated fibrosis and suggested that autocrine and 
paracrine mechanisms could mediate TGF-β dependent effects in epithelial cells and 






Materials and Methods 
Animals  
C57BL/6 mice were kept according to NIH guidelines.  Animal use was approved 
by the University Committee on Use and Care of Animals at the University of Michigan. 
Primary and immortalized renal epithelial cells     
Primary renal epithelial cells were isolated from the cortex of 5-6 week old female 
mice.  Briefly, the medulla was manually removed an cortex was digested by liberase 
DH (Roche) in Dulbecco's modified Eagle's medium (DMEM, Lonza). The tissue 
fragments were sieved through a 212 µm pore size mesh.  After three washes with cold 
DMED, cells were expanded in UltraMDCK serum free mdium (Roche) supplied with 
0.5X Insulin-Transferring-Ethanolamine-Selenium (ITES, Lonza), 60 µg/L Epidermal 
Growth Factor (EGF, R&D systems), 10-9M triiodothyronine and 1X antibiotic 
antimycotic (Gibco). Cells were split and frozen in Fetal Bovine Serum (FBS, Gibco) with 
10% dimethyl sulfoxide.  Recombinant human TGF-β1 and Wnt11 were from R&D 
systems.  
To inhibit translation, cycloheximide (5 µg/mL, Sigma) was added half an hour 
before TGF-β treatment (10 ng/mL) for the indicated times. To inhibit Smad3 
phosphorylation, Specific Inhibitor of Smad3 (SIS3, igma) was added into the medium at 
the concentration of 5 µM 1 hour before 10 ng/ml TGF-β1 treatment for 24 hours.  To 
inhibit JNK signaling, 20µM SP600125 (Sigma) or 10µM JNK inhibitor III (EMD) was 
added into the medium 1 hour before 10 ng/ml TGF-β1 treatment for 24 hours.  To inhibit 
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Wnt signaling, Sfrp1 (R&D systems) was added at 0.5 µg/mL together with 10 ng/mL 
TGF-β1 for 24 hours 
Immortalized renal epithelial cells (TKPTS) were a kind gift from Dr. Bello-Reuss.  
Cells were cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F-12, Gibco) with 2% FBS, 1X ITES and Penicill n Streptomycin (Gibco). 
UltraMDCK serum free medium was used when serum starvation was necessary.   
To overexpress Smad3 or Wnt11, TKPTS cells were cultured on 6 well plate in 
UltraMDCK serum free medium and transfected with 3 µg DNA of Smad3 or Wnt11 
expressing vector or SHS (sonicated herring sperm) DNA control  using Fugene6 (Roche) 
as per manufacturer’s instruction. TGF-β1 at the indicated concentrations was added into 
the medium 24 hours after transfection and cells were cultured for an additional 24 hours.  
Microarrays expression analysis  
PRECs were grown on 100 mm dishes until confluency reached 80%. 
Cycloheximide (5ug/mL) was added half an hour before TGF-β1 treatment (10 ng/ml) for 
4 hours. RNA was extracted using the TRIzol RNA isolati n system (Invitrogen).  All 
samples were done in triplicate.  Gene expression microarray analysis was done by the 
University of Michigan Comprehensive Cancer Center (UMCCC) Affymetrix and 
Microarray Core Facility.  Briefly, The FL-Ovation cDNA Biotin Module V2 kit (NuGEN 
Technologies, San Carlos, CA) was used to produce biotin-labeled cRNA, which was then 
fragmented and hybridized to a Mouse 430 2.0 Affymetrix GeneChip 3 expression arrays 
(Affymetrix, Santa Clara, CA).  Array hybridization, washes, staining, and scanning 
procedures were carried out according to standard Affymetrix protocols.  Expression data 
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were normalized by the robust multiarray average (RMA) method and fitted to weighted 
linear models in R, using the affy and limma packages of Bioconductor, respectively 
(Irizarry et al., 2006; Smyth, 2004). Only probe sets with a variance over all samples 
superior to 0.1, a p-value inferior or equal to 0.05 after adjustment for multiplicity using 
the false discovery rate (Benjamini and Hochberg, 1995), and a minimum 2-fold 
difference in expression were selected for the analysis. 
Western blot analysis 
Cells were directly lysed in 2X SDS buffer (4% sodium dodecyl sulfate, 20% 
glycerol, 0.2M dithiothreitol, 125 mM Tris, pH 6.8) and boiled at 94°C. Samples were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to PVDF membranes and immunoblotted with antibodies as indicated. Rabbit 
anti-phosphorylated Smad3, rabbit anti-Wnt11 and rabbit anti-phosphorylated CamKII are 
from Abcam.  Rabbit anti-Smad2/3, rabbit anti-phosphorylated Smad2, rabbit anti-
phosphorylated JNK, rabbit anti-phosphorylated c-Jun and rabbit anti-c-Jun are from Cell 
Signaling.  Mouse anti- SMA, mouse anti -flag and mouse anti β-tubulin are from Sigma-
Aldrich.  Mouse anti-activeβ-Catenin is from Millipore.  Mouse anti β-Catenin is from 
BD transduction Lab. Mouse anti-N-Cadherin is from Upstate.  HRP-linked secondary 
antibodies and ECL reagent are from GE healthcare.  
RNA reverse-transcription and real-time PCR  
2-3 µg total RNA was reverse-transcribed into comple entary DNA with 
SuperScript First-Strand Kit (invitrogen).  The cDNA products were diluted 5 times and 
amplified with the iTaq Sybr green master mix (Bio-Rad) in a Prism 7500 (Applied 
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Biosystems).  Primers pairs for PCR are as follows: Wnt11 5’-
GGGCCAAGTTTTCCGATGCT, 5’-TTCGTGGCTGACAGGTAGCG; ZEB1 5’-
TCAAGTACAAACACCACCTG, 5’-TGGCGAGGAACACTGAGA; PAI1 5’-
ACATGTTTAGTGCAACCCTG, 5’-GGTCTATAACCATCTCCGTG; Snai1 5’-
GGAAGCCCAACTATAGCGA, 5’-AGCGAGGTCAGCTCTACG; Fzd7 5’-
GAAGCTGGAGAAGCTGATGG, 5’-ATCTCTCGCCCCAAACTCT; Axin2 5’-
TGAGCTGGTTGTCACCTACT, 5’-CACTGTCTCGTCGTCCCA; Wisp1 5’-
GCCAGAGCAGGAAAGTCG, 5’-TACTTGGGTCGGTAGGTGC; GAPDH 5’-
ACCACAGTCCATGCCATCAC, 5’-TCCACCACCCTGTTGCTGTA. 
shRNA mediated Gene knocking-down  
TKPTS cells were seeded on the 6 well plate 1 day before transfection.  Cells were 
transfected with 2 µg DNA of Wnt11 shRNA lentivirus vector 54666, 53302 and a 
scrambled shRNA lentivirus vector (Open Biosystems) u ing Fugene6.  For Smad3 or 
Fizzled7 knockdown, TKPTS cells were infected with lentivirus expressing Smad3 
shRNA 54904 or Fzd7 64762 (Open Biosystems) in the presence of 8 µg/mL polybrene 
and kept overnight.  Puromycin (Sigma-Aldrich) was added into the medium at 10 µg/ml 
and kept in culture medium for constitutive selection. Survival cells were cultured, 
expanded and frozen for further experiments.   
Packed Wnt11 53302 shRNA lentivirus was used to knoc d wn in PRECs.  Cells 
were seeded on 100 mm dishes for 24 hours. Lentivirus was added with 8 µg/mL 




Luciferase assays  
TKPTS cells were seeded on 12 well plates.  3TP-lux reporter vector was 
transfected (1 µg/well) together with SHS or Smad3 expressing vector (2 µg/well) into the 
cells in triplicate 24 hours later.  TOPFLASH or FOPFLASH reporter vector was 
transfected (1 µg/well) together with SHS or Wnt11 expressing vector (2 µg/well). Cells 
were lysed 48 hours after the transfection with dual l ciferase assay kit (Promega) and 
results were read.  In assays requiring TGF-β1 or LiCl treatment, TGF-β1 (10ng/ml) or 
LiCl (20 mM) was administrated 24 hours after the transfection and kept for another 24 
hours. 
Cellular fraction extraction  
PRECs were treated with Wnt11 (500 ng/mL) or LiCl (20 mM) for 24 hours. To 
extract cytoplasma fraction, cells were washed with PBS once, scraped off and lysed in 
cell lysis buffer (5mM PIPES at pH 8.0, 85mM KCl, 0.5%NP40 and 1X protease 
inhibitors) on ice for 10 min. Then, the cells were spun at 3000 rpm for 5 min and 
supernatant was collected as cytoplasmic fraction. T  extract nucleus fraction, cells were 
scraped off, resuspended in 5mL nuclear buffer 1 (10mM Tris at pH 8.0, 10mM NaCl, 
3mM MgCl2, 0.5mM DTT, 0.1% Triton X-100, 0.1M sucrose and 1X protease inhibitors) 
and dumped 20 times with a loose fitting (type A) dounce homogenizer. Then, 5 mL 
nuclear buffer 2 (10mM Tris at pH 8.0, 10mM NaCl, 3mM MgCl2, 0.5mM DTT, 0.1% 
Triton X-100, 0.25M sucrose and 1X protease inhibitors) was added and mixed. At last, 
2.5 mL nuclear buffer 3 (10mM Tris at pH 8.0, 5mM MgCl2, 0.5mM DTT, 0.33M sucrose 
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and 1X protease inhibitor) was added from the bottom. The whole lysate was spun at 2000 
rpm for 5 min at 4oC. The pellet was collected as nuclear fraction. 
Immunofluorescence 
PRECs were seeded on 4 well chamber slide (Thermo Fisher) over night and 
treated with 10 ng/mL TGF-β1or 0.5µg/mL Wnt11 for 24 hours or 1µM Ionomycin 
(Fisher) for 1 hour. Cells were washed with PBS once, fixed in 4% paraformaldehyde and 
permeabilized in PBS containing 0.5% Triton X-100. PBS containing 0.1% Tween20 was 
used to wash slides after the incubation with primay and secondary antibodies. Mouse 
anti β-Catenin is from BD transduction Lab. Rabbit anti-CamKII is from Abcam. Goat 
anti-rabbit IgG-TRITC and Goat anti-mouse IgG-FITC are from Sigma-Aldrich. 4’,6-
diamidino-2-phenylindole dihydrochloride (Dapi) is from Sigma-Aldrich.   
Results 
Primary renal epithelial cells respond to TGF-β in a dose and time dependent manner 
The effects of TGF-β on various cells in culture have been studied in detail (Scheel 
et al., 2011; Yang and Liu, 2001; Zeisberg et al., 2007).  To confirm that primary renal 
epithelial cells (PRECs) from the adult kidneys respond to TGF-β, we isolated cells from 
adult mouse kidneys and cultured them in a defined serum-free medium.   
Once the digested renal tubules were placed on the culture dishes, they would stick 
to plates. After 4-5 days of culture, renal epithelial cells spread out from the tubules and 
formed islands with clear boundaries. Other cell types, such as podocytes and blood cells, 
cannot grow in this conditional medium and were lost after the first passage (Fig 2-1A). 
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When PRECs were exposed to TGF-β1, cells detached from each other and 
migrate out of the islands (Fig 2-1B).  Mesenchymal rkers were activated in those cells, 
although the kinetics of activation varied among different markers. The genes encoding 
αSMA, Zeb1, Pai1 and Snail1 were more sensitive to TGF-β1 with a response in 24 hours, 
while the up-regulation of N-cadherin became obvious by 48 hours (Fig. 2-1D, E). A 
significant decrease of E-cadherin in protein level was not observed until 72 hours (Fig. 2-
1C). The effects of TGF-β at a low dose (0.5ng/ml) were limited. When the dose f TGF-
β1 was increased to 2 ng/ml or 10ng/ml, its ability to change cell morphology and gene 
expression profile was significantly increased. These data indicated that the primary 
isolated cells showed a consistent and dose dependent response to TGF-β and activate 
genes associated with a more mesenchymal phenotype. 
TGF-β1 induced a global gene expression change in PRECs 
Once we had established the effects of TGF-β1 on PRECs in vitro, we sought to 
determine more precisely what genes are directly under the control of TGF-β1. Thus, we 
derived PRECs from adult (5-6 weeks) mouse kidneys and cultured them in serum free 
media for 2 passages before splitting into replicates for our screening strategy. Cells were 
then cultured with cycloheximide (CHX) to inhibit further protein synthesis so only 
mRNAs of direct TGF-β targets would be activated. Subsequently, TGF-β1 was added and 
RNA prepared after 4 hours incubation. Total RNA from PRECs treated with TGF-β1 and 
cycloheximide was compared to RNA from cells cultured with cycloheximide alone using 
Affymetrix Mouse 430 2.0 cDNA microarrays. Three independent samples for each group 
were hybridized and statistically significant changes noted.  
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Overall, 454 Affymetrix probe sets, representing at least 318 annotated unique 
genes, showed significantly altered RNA expression levels of at least 2 fold or greater.  Of 
these, 248 genes exhibited increased expression levels, whereas 70 genes showed a 
decrease in RNA levels, 4 hours post TGF-β1 treatment (Table 2-1). In terms of molecular 
functions, 127 genes were assigned to functional groups involved in DNA binding or 
transcription regulation.  More than 21 kinases showed changed expression levels, 
whereas 19 receptor binding proteins were altered. Given the effects of TGF-β on cell 
migration and dissociation, it was also noted that 12 GTPase regulatory proteins showed 
changed expression levels. Among those genes, 10 genes were associated with Wnt 
signaling pathway (Table 2-2). These include 4 Wnt ligands (Wnt1, Wnt9a, Wnt10a and 
Wnt11), 4 transcriptional factors (Tle1, Nfatc2, Nfatc3 and Sox17), 1 secreted protein 
(Wisp1) and 1 cyclin protein (Ccdn2). For further study, we would focus on Wnt11 
because previous work suggested the cross-talk between Wnt11 and TGF-β (He et al., 
2009; Schiro et al., 2011). 
Activation of Wnt11 by TGF-β1 was Smad3-dependent  
First, we used qRT-PCR to insure that the change in Wnt11 mRMA levels was 
accurate in Affymetrix datasets. Up-regulation of Wnt11 in the presence of cycloheximide 
was confirmed in PRECs and also in an immortalized renal epithelial cell line TKPTS that 
expresses SV40 large T antigen (Ernest and Bello-Reuss, 1995). While Wnt11 up-
regulation could be seen as early as 2 hours after TGF-β addition in PRECs, up-regulation 
in TKPTS cells was a bit slower but still robust (Fig 2-2 A, B). 
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Smad2 and Smad3 are the most critical mediators in TGF-β signaling pathway. 
Although both Smad2 and Smad3 are phosphorylated after TGF-β stimulation, their 
functions are not necessarily similar.  In recent studies utilizing TGF-β mediated animal 
models of fibrosis, Smad2 activation was protective while Smad3 functions as an enhancer 
of the disease phenotype (Meng et al., 2010). Thus, we asked whether Wnt11 up-
regulation was mediated by Smad3. In PRECs, the induction of Wnt11 mRNA was TGF-β 
dose-dependent, in a range from 2 ng/ml to 10 ng/ml (Fig. 2-2C). The fold change of 
Wnt11 mRNA level correlated with the amount of phosphorylated Smad3 (Fig. 2-2G).  A 
specific Smad3 inhibitor, SIS3, which blocked its phosphorylation upon TGF-β treatment 
(Jinnin et al., 2006), abolished the activation of Wnt11 by TGF-β (Fig. 2-2D, H). In 
TKPTS, Wnt11 mRNA level was up-regulated by transiet transfection of Flag-tagged 
Smad3 vector (Fig. 2-2E). This activation was due to phosphorylation of transfected 
Smad3 without TGF-β and was further enhanced with TGF-β treatment (Fig. 2-2I). Next, 
we used an shRNA lentivirus to specifically knockdown Smad3 in TKPTS. After 
puromycin selection, Smad3 protein level was signifcantly knocked down, while Smad2 
protein level remained the same (Fig 2-2J). Both the basal and activated Wnt11 expression 
levels were reduced in the Smad3 knockdown group, consistent with the decreased basal 
and TGF-β activated P-Smad3 in this group (Fig. 2-2F). We also checked the P-Smad2 
level under different conditions mentioned above. Nither the Smad3 inhibitor in PRECs 
nor the modulation of Smad3 proteins in TKPTS affected the response of Smad2 to TGF-β 
(Fig 2-2H, I, J). Considering the Wnt11 expression change in those conditions, our results 




Wnt11 enhances activation of TGF-β dependent mesenchymal markers 
In epithelial cell culture, TGF-β activates a program of mesenchymal marker gene 
expression associated with the transition of epithelial cells to a more mesenchymal 
phenotypes. We thus tested whether Wnt11 induction helped mediate this TGF-β 
dependent EMT in vitro. In addition to the myofibroblast marker αSMA, we examined 
cells for activation of the mesenchymal markers Zeb1, Pai1, and Snail1.  Recombinant 
Wnt11 by itself did not activate any mesenchymal marker gene.  At a high dose of TGF-β 
(10 ng/ml) all of the mesenchymal markers were activ ted by 24h.  However, at lower 
dose of TGF-β (2ng/ml), recombinant Wnt11 significantly enhanced the expression of 
αSMA and other mesenchymal marker genes (Fig. 2-3A, B). Using a Wnt11 expression 
plasmid, a similar effect was observed in TKPTS, as both Pai1 and Snail1 expression 
increased significantly upon TGF-β treatment and Wnt11 expression (Fig. 2-3C). 
Block of Wnt11signaling abolishes the up-regulation of mesenchymal genes 
induced by TGF-β 
Since endogenous Wnt11 is activated by TGF-β, a better test for Wnt11's 
contribution to EMT in vitro is to knockdown endogenous Wnt11 and test for TGF-β 
activation of target genes. Thus, we used shRNA lentivirus to produce two stable cell lines, 
53302 and 54666, derived from the immortalized renal cell line TKPTS.  In cell line 
53302, basal Wnt11 expression was reduced by approximately 60% compared to a 
scrambled control line and Wnt11 was not activated by TGF-β (Fig 2-4A). The up-
regulation of Pai1 was abolished in these Wnt11 knoc d wn cells, while up-regulation of 
Zeb1 and Snail1 were also reduced (Fig. 2-4C).  In the 54666 cell line, basal Wnt11 
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expression was reduced by approximately 40%. However, th se cells up-regulated Wnt11 
about two folds in response to TGF-β1, though this was still significantly less than the 
scrambled control cells (Fig. 2-4B). Nevertheless, the up-regulation of EMT marker genes 
was also attenuated in the 54666 Wnt11 knockdown cells (Fig. 2-4D). Moreover, 
administration of Wnt11 recombinant protein totally rescued the TGF-β dependent up-
regulation of Zeb1 and partially rescued the PAI1 and Snail1 in the 53302 cells (Fig. 2-
4E). We also used the Wnt11 specific 53302 shRNA lentivirus for knockdown in PRECs. 
Although the basal Wnt11 expression was not affected, its up-regulation upon TGF-β 
treatment was largely reduced, as were the response f EMT marker genes and the 
expression of αSMA (Fig. F, G, L).   
We also determined if Frizzled7 (Fzd7), a well-characterized Wnt11 receptor 
(Djiane et al., 2000; Yamanaka and Nishida, 2007), was important for mediating the TGF-
β effects in EMT. Although Fzd7 was expressed in TKPS, its expression was not 
affected by TGF-β treatment. Fzd7 shRNA lentivirus knocked down approximately 60% 
of its expression (Fig. 2-4H).  Similar to Wnt11 knockdown, the activation of 
mesenchymal marker genes, especially Zeb1 and Pai1,in response to TGF-β was reduced 
in the Fzd7 knockdown cell lines (Fig. 2-4I). Lastly, we inhibited Wnt signaling by 
addition of the secreted frizzled related protein Sfrp1, which sequesters Wnt away from its 
receptors. Similar to Fzd7 knockdowns, Sfrp1 addition significantly inhibited the 
expression of mesenchymal genes after TGF-β addition (Fig. 2-4K). Taken together, these 
data indicate that Wnt11 is an important TGF-β target for promoting the activation of 
mesenchymal marker genes in renal epithelial cell lines. 




Our data suggests that Wnt11 is an important autocrine mediator of the TGF-β 
response.  To rule out that Wnt11 functions by modulating the levels of P-Smad3, we 
performed additional assays. First, Wnt11 knockdown did not by itself affect the ability of 
TGF-β to phosphorylate Smad3 in TKPTS (Fig. 2-5A). This was confirmed using a Wnt11 
expression plasmid in TKPTS. If anything, Wnt11 overexpression reduced P-Smad3 
slightly (Fig. 2-5B). We also tested the effects of Wnt11 on the 3TP-Lux reporter plasmid 
that responds to TGF-β. Overexpression of Wnt11 did not activate 3TP-lux by itself and 
Wnt11 knockdown did not affect the ability of TGF-β to activate 3TP-Lux (Fig. 2-5C, D). 
Thus, the effects of Wnt11 on TGF-β activation of mesenchymal markers are not mediated 
through alterations of P-Smad3 levels. 
Wnt11 does not activate canonical Wnt/β-Catenin signaling pathway 
Wnt11 could be functioning through the canonical Wnt/β-catenin pathway, either 
as a target or as an activator thereof during development process or in cancer cells (Cha et 
al., 2009; Dwyer et al., 2010; Zhou et al., 2007). Thus, we checked whether Wnt11 
activated canonical signaling pathway by western blotting, gene expression, and reporter 
assays in our system. In PRECs, administration of Wnt11 recombinant protein failed to 
increase neither the active form of β-catenin, nor the β-catenin level in the nuclear fraction 
(Fig. 2-6A, B). To our notice, the basal nuclear β-catenin level was relative high in PRECs. 
However, this was consistent with a previous report that there were more nuclear β-
catenin proteins in renal epithelial cells than other cell types, such as adult mesenchymal 
stem cells (Jian et al., 2006). Two target genes for canonical Wnt signaling pathway, 
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Axin2 and Wisp1, were also unresponsive to Wnt11 (Fig. 2C). In TKPTS, Wnt11 did not 
activate the TOPFLASH reporter for canonical Wnt signaling pathway (Fig. 2D). 
Conversely, Wnt11 overexpression slightly reduced the basal expression level of 
TOPFLASH, consistent with previous studies that show non-canonical Wnt signaling 
pathway could inhibit canonical Wnt signaling (Abdul-Ghani et al., 2011). These data 
showed that Wnt11 was not activating canonical Wnt signaling in renal epithelial cell 
cultures. Furthermore, there was little evidence that TGF-β activated canonical Wnt 
signaling when using TOPFLASH reporters or by assaying levels of Axin expression after 
4h in the microarray based screens. 
Both TGF-β and Wnt11 activates non-canonical/JNK Wnt signaling, but not non-
canonical/CamKII-associated Wnt signaling 
Since Wnt11 did not activate canonical/β-Catenin Wnt signaling, we then asked 
whether the non-canonical Wnt signaling pathway wasactivated in TGF-β mediated EMT. 
The cJun-N-terminal Kinase (JNK) signaling pathway is one branch of non-canonical Wnt 
signaling. We found that phosphorylation of cJun and total cJun was elevated after TGF-β 
administration (Fig. 2-7A). The calcium-dependent signaling pathway is a second branch, 
in which calcium influx will eventually cause the activation and autophosphorylation of 
Ca2+/calmodulin dependent protein kinase (CaMKII) (Barria et al., 1997; Kuhl et al., 
2000). To our surprise, the basal phosphorylation level of CaMKII in PRECs was high 
even without TGF-β treatment. After TGF-β administration, the amount of phosphorylated 
CaMKII increased only slightly (Fig. 2-7A). Recombinant Wnt11 administration in 
PRECs or overexpression in TKPTS by itself could activ te the JNK signaling pathway as 
evidenced by P-cJun levels (Fig. 2-7B). Under normal conditions, phosphorylated CamKII 
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was present on the plasma membrane and throughout cytoplasma. In the stimulation of 
ionomycin, which enhanced Ca2+ influx by releasing stored intracellular Ca2+ (Morgan and 
Jacob, 1994), phosphorylated CamKII translocated into the nucleus in a number of PRECs. 
However, such translocation was seldom found in TGF-β or Wnt11 treated PRECs (Fig. 2-
8). To test the role of JNK signaling more directly, we used two specific JNK inhibitors, 
SP600125 and JNK inhibitor III, to block JNK signali g in PRECs prior to TGF-β 
administration. The JNK inhibitor III was a cell-permeable 37-mer peptide by fusing 
human c-Jun δ domain (amino acids 33-57) sequence with that of HIV-TAT protein 
transduction domain (amino acids 47-57) via a γ- minobutyric acid spacer. It has been 
shown to specifically disrupt c-Jun/JNK complex formation and the subsequent 
phophorylation and activation of c-Jun by JNK and could be used as a complement 
inhibitor for SP600125 (Holzberg et al., 2003; Wang et al., 2008). Both the inhibitors 
blocked the up-regulation of mesenchymal genes induce  by TGF-β without affecting P-
Smad3 levels (Fig. 2-7C, D). However, despite their common blockade effects on cJun 
phosphorylation, SP600125 decreased the total cJun, while JNK inhibitor III slightly 
increased it. This may reflect the different characteristics of the two inhibitors. Similarly, 
in TKPTS, both the inhibitors reduced the up-regulation of mesenchymal genes induced 
by Wnt11 overexpression (Fig. 2-7E). A more precise examination of Wnt11 expression 
upon the TGF-β treatment showed that Wnt11 was induced as early as 1 hour after TGF-
β1 administration, which was just the time point that the amount of phosphorylated c-Jun 
began to elevate (Fig. 2-7F, G). The addition of cycloheximide abolished c-Jun 
phosphorylation, suggesting that the activation of JNK signaling pathway upon TGF-β 
treatment required new protein synthesis. Also, Wnt11 knockdown suppressed TGF-β 
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induced c-Jun phosphorylation, which is consistent with a role for Wnt11 in activating the 
JNK pathway (Fig. 2-7H).  Taken these together, ourresults demonstrated that up-
regulation of Wnt11 by TGF-β drives expression of mesenchymal genes through the non-
canonical, JNK signaling pathway. 
Discussion 
Despite the critical role of TGF-β in renal fibrosis, many of its target genes and 
biological effects in renal epithelial cells remain poorly characterized.  We systematically 
analyzed the effects of TGF-β on transcription of direct target genes using renal pithelial 
cells and translation inhibition. From the microarray result, we found that more than 300 
genes changed their RNA expression levels of at least 2 fold.  In the presence of 
cycloheximide, not all mesenchymal markers, such as P i1 and Zeb1, were up-regulated 
by TGF-β, suggesting that these genes are not direct targets of Smad protein dependent 
transcription.  This was consistent with previous studies indicating that some 
mesenchymal markers, such as Pai1, were not directly regulated by Smad proteins, but the 
targets of other transcriptional factors induced by TGF-β signaling (He et al., 2010). 
Similarly, E-cadherin was also not on the list. This is not only because that the suppression 
of E-cadherin required new protein synthesis, such as Snail1 (Vincent et al., 2009), but 
also due to a short TGF-β treatment time (Yang and Liu, 2001).  
Among the genes activated by TGF-β were many associated with the Wnt 
signaling pathway.  Recent evidence implied that Wnt signaling, especially the canonical 
Wnt/β-catenin pathway, was involved in EMT and TGF-β mediated fibrosis (Akhmetshina 
et al., 2012; He et al., 2009; Surendran et al., 2005; Zhou et al., 2012a).  In our studies, 
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Wnt11 showed the greatest response to TGF-β both in microarray and real-time PCR 
assays and was thus studied further.  Prior studies also suggested that Wnt11 was directly 
regulated by β-Catenin (Dwyer et al., 2010; Zhou et al., 2007). In our study, LiCl 
treatment could activate Wnt11 expression in PRECs (data not shown). However, TGF-β 
did not activate the expression of Axin2, a typical β-Catenin target, in our microarray 
studies, indicating that at least in the early stage, the upregulation of Wnt11 by TGF-β was 
β-Catenin independent. In the Smad3 knockdown TKPTS cells, the Smad2 
phosphorylation upon TGF-β treatment was not affected, but Wnt11 up-regulation was 
largely reduced, suggesting that Smad2 alone is not ufficient to activate Wnt11. In Smad3 
overexpressed TKPTS, the transfected Smad3 was phosphorylated and activated Wnt11 
expression, without affecting Smad2 phosphorylation status. Taken this together, our data 
clearly shows that Wnt11 activation is through a Smad3 dependent mechanism. Since 
Wnt11 was critical for the upregulation of mesenchymal genes upon TGF-β1 treatment, 
our results supported the different roles of Smad2 nd Smad3 in mediating EMT and renal 
fibrosis (Meng et al., 2010). Considering the protecting effects of Smad2 in renal fibrosis, 
it is interesting to test whether Smad2 overexpression will inhibit Wnt11 upregulation by 
TGF-β. Another issue concerning the direct regulation of Wnt11 by Smad3 proteins, is to 
find the Smad binding element(s) (SBE) in the promoter region of Wnt11. There are 6 
transcripts for Wnt11 in mouse genome, sharing two promoter regions. Representatively, 
Wnt11-001 (ENSMUST00000067495) has 7 exons, while Wnt11-201 
(ESMUST00000168655) starts roughly from the exon3 of Wnt11-001 with 5 exons. Both 
promoter regions have been cloned previously and found to be regulated by β-Catenin  
(Dwyer et al., 2010; Zhou et al., 2007). In our study, we also cloned a 2kb genome DNA 
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fragment from these two promoter regions and inserted them into a luciferase reporter 
vector. However, both Wnt11 promoter reporters failed to response to TGF-β1 or Smad3 
overexpression in either TKPTS or 293 cells (data not shown). Thus, finding real SBE in 
Wnt11 promoter regions, a chromatin immunoprecipitation (ChIP) assay with Smad3 
antibody would be necessary. Furthermore, it has been r ported that Smad proteins also 
bound to enhancers to regulate target gene expression (Tone et al., 2008). Thus, a 
conserved region between the exon4 and exon5 (in case of Wnt11-201) is another 
candidate for the ChIP assay. 
Wnt11 has multiple functions in regulating cell proerties, such as proliferation, 
migration and differentiation.  However its precise function in different cell types was 
context dependent and sometimes contradictory.  For example, Wnt11 enhanced tight and 
gap junction formation in a quail mesodermal cell line QCE6 to promote its differentiation 
to cardiomyocytes (Eisenberg et al., 1997).  In contrast, Wnt11 conditional medium 
induced E-cadherin internalization in a rat intestinal epithelial cell line IEC6, thus 
increasing its proliferation and migration (Ouko et al., 2004).  These data suggested that 
Wnt11 effects were highly dependent on the cellular context.  Although it was shown that 
Wnt11 was involved in EMT during dorsal fin development in Xenopus (Garriock and 
Krieg, 2007), its detailed function and mechanisms of action were not well characterized.  
Here, we reported that Wnt11 participated in TGF-β mediated EMT in both primary and 
immortalized renal epithelial cells, and was necessary for the up-regulation of 
mesenchymal gene expression induced by TGF-β. Although both Wnt11 administration in 
PRECs and transfection in TKPTS could enhance TGF-β effects, its treatment alone in 
two cell types was different. In PRECs, Wnt11 alone did not activate mesenchymal 
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markers; however, in TKPTS, Wnt11 up-regulated some f the mesenchymal genes.  This 
could result from subtle differences of cell characteristics between primary and 
immortalized cells and Wnt11 delivery methods.  Recombinant protein administration is 
more like a paracrine model, whereas expressing vector transfection may be more 
autocrine. Compared to the Wnt11 recombinant protein, the autocrine Wnt11 in TKPTS 
may interact with other secreted ligands, thus acquiring additional properties. For example, 
the secreted Xenopus Wnt11 physically interacts with Wnt5a and the complexes has more 
canonical Wnt signaling activity than secreted Wnt11 or Wnt5a acting alone (Cha et al., 
2009).   
Whether Wnt11 activates the canonical Wnt signaling pathway is also 
controversial.  For example, Cha SW et al (Cha et al., 2009) showed that Wnt11/5a 
complex could enhance canonical Wnt11 signaling through accumulating cytosolic β-
catenin in Xenopus ooctyes, mouse L cells and human embryonic stem cells. Other reports 
show that Wnt11 had no effect, and even down-regulated β-catenin signaling (Anton et al., 
2007; Maye et al., 2004). To date, most studies are consistent with Wnt11 activating the 
non-canonical Wnt signaling pathways through the JNK or CamKII kinases (Flaherty et 
al., 2008; Westfall et al., 2003; Zhou et al., 2007). In our renal epithelial cells, Wnt11 
alone did not activate canonical Wnt signaling nor was the CamKII protein activated by 
TGF-β or Wnt11 directly. In fact, CamKII reportedly can i activate Smad/TGF-β 
signaling through blocking the accumulation of nuclear Smad proteins (Wicks et al., 2000).  
Clearly this was not the case given the robust TGF-β responses observed. However, we 
did measure activation of the JNK signaling pathway by TGF-β and Wnt11. The 
abolishment of c-Jun phosphorylation induced by TGF-β in the presence of cycloheximide 
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indicated that the activation of JNK signaling was a econdary effect for TGF-β, which 
required new protein synthesis. Activation of JNK was critical for mediating the 
Wnt11/TGF-β response because inhibition of JNK signaling could decrease up-regulation 
of the mesenchymal genes induced by Wnt11. Although JNK signaling was activated by 
Wnt11 alone in PRECs, this was not sufficient to induce expression of mesenchymal 
genes. The JNK inhibitor only attenuated the effects of TGF-β, but did not entirely block 
the activation of mesenchymal genes. 
Furthermore, by activating families of secreted signaling molecules, TGF-β acting 
on epithelial cells could impact the environment and the adjacent cells in the renal 
interstitium. Nowadays, more and more evidence pointed to pericytes for the increasing 
number of fibroblasts in renal fibrosis (Humphreys et al., 2010; Lin et al., 2008). In this 
model, pericytes detached from the vasculature, migrate into interstitium, proliferate and 
differentiate into myofibroblasts. However, the signaling pathways controlling this series 
of biological process are largely unknown. It has been reported that Wnt11 was 
upregulated during renal fibrosis (He et al., 2009), also it promoted cell survival, 
migration and proliferation in different types of cells (Garriock and Krieg, 2007; 
Matthews et al., 2008; Ouko et al., 2004; Uysal-Onganer et al., 2010). Thus, it is worth 
exploring the function of Wnt11 in pericyte activation during renal injury.   
Taken together, our results showed that TGF-β activates multiple signaling 
pathways in renal epithelial cells through enhanced expression of secreted signaling 
proteins and transcription factors.  Of these, Wnt11 activation by TGF-β enhances the 
overall effects attributed to TGF-β on epithelial cells, such as expression of genes 
associated with more mesenchymal cells.  A recent study on EMT in breast tumor 
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suggested the importance of TGF-β, canonical and non-canonical Wnt signaling 
pathways in maintaining the mesenchymal state, indicating an interactive communication 
model between different signaling pathways in a biological process (Scheel et al., 2011).  
Our findings suggested a transregulation model, whereby TGF-β directly activates 









Figure 2-1.Effects of TGF-β on primary renal epithelial cells. A) Phase contrast 
micrographs of morphology change of PRECs after they w re isolated from mouse cortex. 
Indicated times were the days after cells were isolated. B) Phase contrast micrographs of 
PRECs treated with increasing concentrations of TGF-β  for 24 h. C) Western blot of 
cells treated for 0, 48, 72 h with 10 ng/ml of TGF-β and probed for E-cadherin. D) Time 
and dose dependence of αSMA and N-cadherin expression with increasing amounts of 
TGF-β. E) qRT-PCR of mesenchymal markers after 24h TGF-β treatment at the indicated 
doses. All samples were done in triplicate with error bars representing one standard 




Figure 2-2. Wnt11 are direct targets of TGF-β signaling. A) Wnt11 RNA levels in 
PRECs cells cultured with TGF-β for the indicated time in hours in the presence of 
cycloheximide. B) Wnt11 RNA levels in TKPTS cells cultured with TGF-β for the 
indicated time in hours in the presence of cycloheximide. C) Wnt11 RNA levels after 24h 
with varying does of TGF-β as indicated. D) Wnt11 RNA activation in response to TGF-
β in the presence or absence of the Smad3 inhibitor SIS3. E) Wnt11 RNA levels 
measured after Smad3 transfection and/or TGF-β treatment.  F) Wnt11 RNA activation in 
response to TGF-β in the presence or absence of Smad3 shRNAs or scrambled controls.  
G) Western blot of P-Smad3 in response to increasing does of TGF-β. H) Western blots 
of P-Smad3 and P-Smad2 after inhibition by SIS3 and treatment with TGF-β. I) Western 
blot for P-Smad3 and P-Smad2 after Smad3 transfection and TGF-β treatment. J) 
Western blot of P-Samd3, P-Smad2 and total Smad2/3 after culture with Smad3 shRNAs 
and TGF-β treatment. It is noted that Smad3 proteins were shown nearly totally gone in 
Smad2/3 panel, while it is still detectable in the P-Smad3 panel. This resulted from 
different expose time and affinity for these two antibodies. All samples were done in 








Figure 2-3. Wnt11 increases TGF-β dependent activation of mesenchymal genes. A) 
Western blots for N-cadherin, αSMA, P-Samd3, and β-tubulin from cells treated with 
recombinant Wnt11 and different does of TGF-β as indicated. B) Quantitative RT-PCR 
for RNAs from the genes indicated under similar conditions as in A. C) Quantitative R-
PCR for mesenchymal genes after transfection with Wnt11 expression plasmids and/or 
TGF-β addition. All samples were done in triplicate with error bars representing one 
standard deviation (SD) from the mean. (*p < 0.05; **p < 0.01, n.s. not significant, 









Figure2-4. Wnt11 is necessary for the TGF-β dependent activation of mesenchymal 
genes. A) Wnt11 RNA levels after culture with shRNA #53302 or a scrambled control in 
TKPTS cells with or without TGF-β. B) Similar experiment as in A but using the Wnt11 
shRNA #54666. C) The TGF-β induction of RNAs for the indicated genes in the pr sence 
or absence of shRNA #53302. Relative amount of RNA is compared before or after TGF-
β addition and expressed as fold induction. D) Similar experiment as in C but using the 
Wnt11 shRNA #54666. E) The induction fold change of indicated genes by TGF-β is 
measured in cells cultured with shRNA 53302, with shRNA 53302 and recombinant 
Wnt11, or with scrambled shRNA. Note that recombinant Wnt11 increases the induction 
of mesenchymal genes in the presence of 53302. F) Wnt11 shRNA 53302 in PRECs 
reduces TGF-β dependent Wnt11 RNA induction. G) In PRECs, Wnt11 shRNA 53302 
reduces the TGF-β mediated fold induction of mesenchymal marker genes. H) In TKPTS, 
inhibition of Fzd7 RNA by shRNA #64762 is independet of TGF-β. I) Fzd7 shRNA 
#64762 inhibits the TGF-β mediated induction of mesenchymal marker genes. J) The 
Wnt secreted inhibitor Sfrp1reduces the TGF-β mediated induction of mesenchymal 
marker genes in PRECs. K) Western blots for αSMA and Wnt11. Cells show that 
inhibition of Wnt11 by shRNAs reduces the accumulation of αSMA in response to TGF-
β in PRECs. All samples were done in triplicate with error bars representing one standard 







Figure 2-5. Wnt11 does not modulate Smad proteins. A) Western blot of P-Smad3 
from cells cultured with Wnt11 shRNAs and/or TGF-β as indicated in TKPTS. B) 
Western blots from cell overexpressing Wnt11 and treated with TGF-β show no affect of 
Wnt11 on P-Smad3 levels. C) The P-Smad2/3 reporter 3TP-Luc was assayed after co-
transfected with Wnt11 or treatment with TGF-β. Note that Wnt11 does not increase 
3TP-dependent luciferase. D) Wnt11 shRNA knockdown does not affect the ability of 
TGF-β to activate 3TP-luc. All samples were done in triplicate with error bars 














Figure 2-6. Wnt11 does not mediate β-catenin dependent gene activation. A) Western 
blot using antibodies against activated β-catenin show no effects of Wnt11 on activated 
β-catenin accumulation. B) Western blot using antibody against total β-catenin for 
cytoplasmal and nuclear fraction of PRECs under Wnt11 or LiCl treatment for 24h. β-
tubulin and ptip was used as the loading control of cytoplasmal and nuclear fraction 
respectively. C) Wnt11 does not activate Wisp1 or Axin, two known β-catenin target 
genes, as assayed by qRT-PCR in renal epithelial cels. D) Cells were transfected with the 
β-catenin reporter TOPFLASH and treated with Wnt11, TGF-β, or LiCl, or co-
transfected with Smad3.  Only the known GSK3 kinase inhibitor LiCl activated the 
TOPFLASH reporter. FOPFLASH is used as non-specific ontrol plasmid. All samples 
were done in triplicate with error bars representing o e standard deviation (SD) from the 











Figure 2-7. Activation of JNK signaling by TGF-β/Wnt11 activates mesenchymal 
marker genes. A) Western blot for P(S63)-cJun, total cJun and P-CamKII after treatment 
of renal epithelial cells for 24 or 48 hours with TGF-β shows increased P-cJun and total 
cJun but not P-CamKII. B) Addition of recombinant Wnt11 in PRECs and Wnt11 
overexpression in TKPTS increases levels of P-cJun, b t not P-CamKII. C) Western blots 
of cell lysates show that inhibition of the cJun kiase (JNK) by SP600125 or JNK 
inhibitor III reduces expression of αSMA in response to TGF-β. Note there is no affect on 
P-Smad3 levels. D) qRT-PCR of mesenchymal marker genes treated with TGF-β, with or 
without the JNK inhibitors, show reduced expression of all mesenchymal markers tested 
upon JNK inhibition in PRECs. E) Activation of mesenchymal marker gene expression in 
response to Wnt11 is reduced upon JNK inhibition in TKPTS, as determined by qRT-
PCR. F) Wnt11 RNA levels in PRECs cells cultured with TGF-β for the indicated times 
in hours. G) Western blots for P-cJun, total cJun, W t11 and P-Smad3 with TGF-β 
treatment for indicated times absence or in the presence of cycloheximide (CHX). CHX 
abolished the elevated P-cJun and Wnt11 upon TGF-β treatment. H) Western blots for P-
cJun show reduced levels upon TGF-β treatment when cells are cultured with shRNA 
53302 against Wnt11. All samples were done in triplicate with error bars representing 














Figure 2-8. Neither TGF-β nor Wnt11 induced translocation of p-CamKII in PRECs. 
Immunofluorescence for p-CamKII (red) and β-Catenin (green) shows that treatment of 
TGF-β or Wnt11 for 24 hours does not induce the translocati n of p-CamKII into nucleus. 
Ionomycin administration for 1 hour is utilized as the positive control for the activation of 
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Attenuated upregulation of mesenchymal marker genes in unilateral ureteral 




Renal interstitial fibrosis is a common pathology in most chronic and progressive 
kidney diseases. Two main branches of TGF-β superfamily are the direct mediators of 
fibrosis. TGF-β promoted renal fibrosis, while BMP7 is a protector and counteracts TGF-
βs. Recently, our lab discovered a novel cysteine-rich secreted protein, kielin/chordin-like 
protein (KCP), which is an enhancer for BMP signalig, as well as an inhibitor for TGF-β 
signaling. Here, in the unilateral ureteral obstruction (UUO) mouse model, we showed 
that specific overexpression of KCP in renal epithelia significantly attenuated the 
upregulation of mesenchymal marker genes in the injured kidney. Our study 
demonstrated the importance of the balance of TGF-β and BMP signaling in the 
progression of renal fibrosis and provided a new potential therapeutic target for its 
treatment by the application of KCP.   
Introduction 
In the United States, approximately 13% of the adult population suffers some 
degree of chronic kidney disease (CKD) whose prevalence continues to increase (Coresh 
et al., 2007). Clinically, chronic kidney disease i determined by persistent albuminuria 
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and decreased estimated glomerula filtration rate (GFR). Pathologically, the CKD, 
especially at its end stage, is usually accompanied by severe renal interstitial fibrosis (Liu, 
2010). Inflammation, such as the infiltration of macrophages to the injured kidney, plays 
a crucial role in the initiation of renal fibrogenesis (Ricardo et al., 2008), which is 
followed by the proliferation and activation of fibroblast and enhanced deposition of 
extracellular matrix (ECM). The increasing number of fibroblasts, myofibroblasts and 
excess ECM replace the kidney parenchyma, destroy the normal renal tubular 
architecture, and eventually lead to the end stage renal disease (Liu, 2011).  
Among the most well studied signaling pathways in re al fibrotic disease are 
those of the transforming growth factor β (TGF-β) superfamily, the most relevant of 
which are the TGF-βs and BMPs. As we discussed in the Chapter I and II, the general 
signaling transduction pathway for TGF-βs and BMPs is similar (Massague, 1998). The 
binding of the ligand to its type II receptor, leads to the recruitment and phosphorylation 
of type I receptor. The activated type I receptor is a serine/threonine kinase that 
transduces the signal through phosphorylating receptor Smad proteins (R-Smads), which 
form a heteromeric complex with a common partner, Smad4, translocate to the nucleus 
and mediate target gene expression. For TGF-βs, the R-Smads are Smad2 and 3, while 
for BMPs, they are Smad1, 5 and 8. A consensus exists that TGF-βs are pro-fibrogenic 
cytokines, and BMPs counteract the effects of TGF-βs. In vivo studies showed that mice 
genetically overexpressing TGF-β1 (Kopp et al., 1996) or treated with recombinant TGF-
β2 (Ledbetter et al., 2000), suffered renal interstitial fibrosis and tubular atrophy over 
time. Conversely, the severity of renal hisopathology was reduced in experimental 
glomerular nephritis models by treating animals with a human antibody against rat TGF- 
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β type II receptor (Kasuga et al., 2001). Immunohistochemical staining revealed that both 
TGF-β1 ligand and its type I receptor were robustly upregulated in proximal tubular 
epithelial cells of the injured kidney (Yang and Liu, 2001). In vitro, BMP7 reversed the 
TGF-β1 induced epithelial mesenchymal transition. This was supported by the in vivo 
study showing that systemic administration of recombinant human BMP7 led to the 
repair of severely damaged renal tubular epithelial cells and the reversal of chronic renal 
injury (Zeisberg et al., 2003). Furthermore, BMP7 induced mesenchymal to epithelial 
transition (MET) in adult renal fibroblasts (Zeisberg et al., 2005).  
In Chapter I, we have thoroughly discussed the regulation of TGF-β signaling 
both outside and inside of cells. Out of cells, a group of secreted factors, containing the 
cysteine rich (CR) domains, mediates TGF-β signaling transduction through blocking or 
facilitating the binding between ligands and receptors. For example, the crystal structure 
of the Noggin-BMP7 complex directly showed that Noggin inhibited BMP7 by blocking 
the surfaces that were required to interact with the type I and type II BMP receptors 
(Groppe et al., 2002). On the other hand, the secreted CR domain protein, connective 
tissue growth factor (CTGF), not only blocked BMP signaling, but also enhanced TGF-
β1 signaling through direct interaction with TGF-β1 ligands (Abreu et al., 2002).  
Recently, our lab identified kielin/chordin-like protein 1 (KCP1) as a secreted 
protein with 18 cysteine-rich domains that is expressed in the developing kidney at both 
early and late stages (Lin et al., 2005). Unlike Noggin or CTGF, KCP1 enhances BMP 
signaling and inhibited TGF-β1 signaling (Lin et al., 2005; Lin et al., 2006). The KCP 
homozygous mutant mice showed no gross developmental abnormalities, but exhibited 
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enhanced susceptibility to developing renal interstitial fibrosis in both UUO chronic 
kidney disease model and folic acid acute renal injury model (Lin et al., 2005). 
In this chapter, we tried to address whether overexpression of the secreted KCP 
protein in transgenic mice will alter the balance between the TGF-β and BMP signaling 
pathway and change the progress of renal fibrosis. Transgenic mice were engineered to 
express KCP protein specifically in renal proximal tubule cells and subjected to unilateral 
ureteral obstruction. While KCP expression by itself had few measurable deleterious 
effects, KCP transgenic mice showed decreased upreglation of mesenchymal genes in 
injured kidney over time, suggesting a more resistance to interstitial fibrosis. Our studies 
clearly pointed to the renal protective functions for KCP, and provide a potential target 
for the treatment of renal fibrosis.   
Materials and Methods 
Animals 
Mice were kept according to NIH guidelines.  Animal use was approved by the 
University Committee on Use and Care of Animals at the University of Michigan. The 
KCP mice were generated by Dr. Dressler. Pepck promoter was used to drive a myc-
epitope tagged form of the KCP protein that also included a human Igk light chain signal 
peptide to enhance secretion. 
For the induction of renal fibrosis, the UUO model was utilized. Mice were 
anesthetized with intraperitoneal injection of ketamine and xylozine. Through a midline 
abdominal incision, the right ureter was exposed antied off at the mid-ureteral level 
with fine suture materials (4-0 silk) to induce a complete obstruction. Mice were allowed 
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to recover from anesthesia and were kept with ad libitum supply of food and water until 
the indicated time of sacrifice (0, 7, 14 and 28 days). Both obstructed and contralateral 
kidneys were harvested for RNA and protein. The UUO model was generated by Abdul 
Soofi.  
RNA extraction 
The kidney tissue was added into TRizol reagent (Invitrogen) and homogenized 
with Polytron Homogenizer. The mixture was centrifuged and supernatant was collected 
for further isolation following the manufacturer’s instructions. 
RNA reverse-transcription and real-time PCR  
2-3 µg total RNA was reverse-transcribed into comple entary DNA with 
SuperScript First-Strand Kit (Invitrogen).  The cDNA products were diluted 5 times and 
amplified with the iTaq Sybr green master mix (Bio-Rad) in a Prism 7500 (Applied 
Biosystems).  Primers pairs for PCR are as follows: Wnt11 5’-
GGGCCAAGTTTTCCGATGCT, 5’-TTCGTGGCTGACAGGTAGCG; ZEB1 5’-
TCAAGTACAAACACCACCTG, 5’-TGGCGAGGAACACTGAGA; PAI1 5’-
ACATGTTTAGTGCAACCCTG, 5’-GGTCTATAACCATCTCCGTG; Snai1 5’-








Generation of KCP transgenic mice 
Since the Pepck promoter was reported to be very active in renal proximal tubular 
epithelial cells (Short et al., 1992), it was used to drive the expression of transgenic KCP 
gene (Fig. 3-1A). The transgenic KCP protein was myc-epitope tagged and included a 
human IgK light chain signal peptide to enhance its secretion. Founder animals were 
mated to wild-types and subsequent F1 generations ge otyped for the transgene. The 
expression of transgenic KCP varied among littermates, but immunohistochemistry 
results showed that the exogenous KCP protein were most located in proximal tubules 
(Fig. 3-1B and C). The strongest expressing strain w s used for renal injury studies. 
KCP overexpression attenuated the upregulation of mesenchymal genes in UUO model 
In UUO disease model, the normal renal tubular archite ture was destroyed and 
replaced by increasing number of fibroblasts and myofibroblasts. Thus an upregulation of 
mesenchymal marker genes, such as Pai1, Snail1 and Zeb1, in the injured kidney was 
observed. Furthermore, the expression of these mesenchymal markers increased over 
time, indicating the progress of the injury. In KCP transgenic mice, the basal expression 
of mesenchymal genes were not much affected. However their upregulation trends, along 
with the disease progression, were significantly attenuated (Fig. 3-2B). The effect of KCP 
on mesenchymal gene expression was through enhancing BMP signaling and inhibiting 
TGF-β signaling, as indicated by the more phosphorylated Smad1, 5 and 8 proteins and 
less phosphorylated Smad2 and 3 in transgenic mice (Fig. 3-2A). In Chapter II, we 
demonstrated that Wnt11 was a direct target of TGF-β signaling. Here, we found that 
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Wnt11 expression was also reduced by KCP overexpression, further demonstrating the 
inhibitory effect of KCP on TGF-β signaling (Fig. 3-2B). These taken together, our data 
suggested that KCP attenuated mesenchymal gene upregulation in injured kidney through 
enhancing BMP signaling and blocking TGF-β signaling. 
Discussion 
Although BMPs and TGF-βs belong to the same superfamily, their functions in 
renal fibrosis are very different. While TGF-β induced EMT in vitro, and correlated with 
increased fibroblast proliferation and ECM depositin to promote fibrosis in vivo (Iwano 
et al., 2002; Poncelet and Schnaper, 2001; Strutz et al., 2001), BMP7 mediated MET in
vitro, and suppressed inflammation and improved renal recovery in vivo (Hruska et al., 
2000; Vukicevic et al., 1998; Zeisberg et al., 2005). Over the years, drugs have been 
designed to repress TGF-β signaling or enhance BMP7 signaling for the treatment of 
chronic kidney diseases. Our study suggested that KCP may be a better candidate, 
because it can modulate TGF-β and BMP7 at the same time. Furthermore, KCP was not 
widely expressed in adult tissues (Lin et al., 2005), suggesting that drug targeting at KCP 
might cause less side effects. 
Besides the upregulation of mesenchymal marker genes, histology and 
immunostaining showed less Collagen IV deposition and αSMA expression in KCP mice 
compared to wildtype control at 7 and 14 days after UUO (data not shown). These further 
demonstrated the protective role of KCP. The quantit tive PCR was based on the whole 
renal tissue, so we did not know whether the attenuated mesenchymal gene expression 
was due to less proliferation of fibroblasts or reduced EMT effect. However, since the 
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transgenic KCP was overexpressed specifically in proximal tubular epithelia, our results 
indicated the important role of those epithelial cells in promoting renal fibrosis either 
through an autocrine or paracrine manner.  
In the normal adult kidney, the BMP7 signaling is active, but its function is not 
well characterized. The main target cells for the BMP7 signaling in the kidney are 
epithelial cells, especially proximal tubular epithelial cells (Bosukonda et al., 2000). The 
function of BMP7 signaling in those epithelial cells may be to maintain the expression of 
E-cadherin (Zeisberg et al., 2005). It has been report d that BMP signaling was also 
involved in maintaining the pluripotency of stem cells (Varga and Wrana, 2005). During 
renal development, not all metanephric mesenchyme cells aggregate and become 
epithelia. Some cells maintain their mesenchymal prope ties and remain as interstitial 
stromal cells (Dressler, 2006). Thus, BMP7 signaling may be important for the survival 
of these interstitial stromal cells. During renal fibrosis, the decreasing BMP7 signaling 
may contribute to the differentiation of these stromal cells into fibroblasts. Meanwhile, 
the destruction of the stem cell pool may also reduc  the recovery ability of the kidney 
from acute renal diseases. This may be one of the reasons why rats receiving BMP7 








Figure 3-1. Expression of KCP in the transgenic mice. A) Schematic shows the 
expression of transgenic KCP is under the control of pepck promoter. B) Western blot for 
myc from wildtype (#1) or transgenic kidneys (#2 and #3) indicates the transgenic 
expression of KCP proteins. C) Immunofluorescence for myc (red) and laminin (green) 
shows that exogenous KCP is specifically expressed in proximal tubular epithelia. 










Figure 3-2. KCP overexpression attenuated upregulation of mesenchymal genes in 
injured kidney. A) Western blot for P-Smad1, P-Smad3 and myc from three independent 
normal, 7-day or 14-day UUO kidneys of wildtype or KCP transgenic mice. The 
expression of KCP decreased with the progression of the disease. The amount of P-
Smad1 was higher in KCP mice than the wildtype, while the amount of P-Smad3 was 
lower. β-tubulin was the loading control for P-Smad1, Smad1 nd myc. β-actin was the 
loading control for P-Smad3. B) Gene expression levels were assayed by qRT-PCR for 
the indicated genes in control (n=3), 7-day (n=3), and 14-day UUO kidney (n=3) RNA 
isolates. All samples were done in triplicate with error bars representing one standard 
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Tle4 enhances BMP7 mediated gene expression 
Abstract 
Groucho proteins and their mammalian homologues, Transducin-Like Enhancer 
of split (Tle) proteins are common corepressors, and re critical for normal development 
processes. Bone morphogenetic protein 7(BMP7) signaling belongs to transforming 
growth factor-β (TGF-β) superfamily and plays an important role in controlling kidney 
development. However, the regulation of BMP7 signaling, especially within cells, is 
largely unknown. Here, our results showed that overexpression of Tle4 robustly activated 
the expression of a BMP reporter, as well as enhancing and sustaining the upregulation of 
endogenous Id1 gene induced by BMP7. BMP7 administrat on did not affect the 
endogenous level of Tle4. Tle4 activated the BMP repo ter through mediating Smad 
proteins, as Tle4 repressed the expression of Smad7, an inhibitory Smad protein, and 
overexpression of Smad7 totally abolished the effect of Tle4 on the induction of the BMP 
reporter. Our study provided a new mechanism for the regulation of BMP signaling, 
which may be important for the kidney and neural development, since Tle4 and BMP7 
are co-expressed in these developing tissues. 
Introduction 
The human genome is carried by 23 pairs of chromosoe , containing 20,000-
25,000 protein-coding genes (2004). The proper expression of these genes is critical for 
normal cellular physiological processes, such as prolife ation, differentiation and death, 
thus requiring elegant and tight regulation. Two large families of proteins control gene 
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expression, the activators and the repressors. As their name suggested, activators help the 
recruitment of RNA polymers II to the gene promoter and increase target gene expression, 
while repressors condense the chromatin structure, exclude activators and transcription 
machinery, and reduce or even silence gene expression.  
Groucho proteins and their evolutionary conserved mam alian Transducin-Like 
Enhancer of split (Tle) homologues were the first identified metazoan corepressors 
(Cinnamon and Paroush, 2008). Their structure encompasses five domains, the Trp-Asp-
repeat (WDR) domain at the N-terminal, followed by Ser-Pro-rich (SP) domain, a CcN 
domain, and Gly-Pro-rich (GP) domain, with a Gln-rich (Q) domain at the C-terminal 
(Buscarlet and Stifani, 2007). The WDR and Q domain re highly conserved and 
essential for the interaction with other DNA-binding proteins to mediate gene repression 
(Fisher and Caudy, 1998; Jennings et al., 2006). The SP domain could be phosphorylated 
by MAPK, which negatively regulates Gro/Tle repression ability (Hasson et al., 2005). 
The CcN domain has the nuclear localization signals (Buscarlet and Stifani, 2007). The 
Gro/Tle family represses gene expression through multiple mechanisms. First, it interacts 
with TFIIE or other transcriptional factors to prevent the assembling of transcription 
machinery or activator complexes (Buscarlet and Stifani, 2007). Second, Grg3 bound to 
nucleosomal arrays to promote condensation into higher-order chromatin to block the 
access of other transcriptional factors (Sekiya andZaret, 2007). Third, they recruit 
histone deacetylase or other histone modification cmplexes to repress target gene 
expression (Patel et al., 2012; Yochum and Ayer, 2001). Through a series of knockdown 
and overexpression experiments, Gro/Tle proteins play important roles in embryogenesis, 
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body patterning and organogenesis (Dasen et al., 2001; Wang et al., 2004; Zamparini et 
al., 2006).  
Bone morphogenetic protein (BMP) belongs to the transforming growth factor 
(TGF)-β superfamily (Massague, 1998; Patel and Dressler, 2005).  In mammals, the 
binding of BMP ligands to their receptor, BMP type II receptor, leads to the recruitment 
and phosphorylation of BMP type I receptor (BMPRI). The activated BMPRI is a 
serine/threonine kinase that transduces the signal through phosphorylating receptor-
activated Smad1, 5 and 8. Phosphorylated Smad1, 5 and 8 form a heteromeric complex 
with a common partner, Smad4, and translocate to the nucleus to regulate target gene 
expression. The inhibitory Smads (I-Smads, Smad6 and 7) shared a common sequence 
with R-Smads and competed with them to bind to typeI receptor or Smad4, thus blocking 
signaling transduction.  
BMP7 was known to be critical for the normal kidney development. It has been 
reported that the BMP7 null mice died shortly after bi th because of severe renal 
dysfunction (Luo et al., 1995). In vitro, BMP7 promoted the survival of metanephric 
mesenchymal cells, as well as their differentiation t  the diverse epithelial cells types of 
the nephron (Dressler, 2006; Dudley et al., 1999; Vukicevic et al., 1996). This was 
consistent with the in vivo studies, showing that BMP7 null mice had much fewer 
glomeruli and nephrons than the wildtype mice. (Dudley et al., 1995; Luo et al., 1995). 
Besides these genetic data, the BMP type I receptors, as well as their responsive Smads 
(Smad1, 5 and 8) were expressed in the nephrogenic zo e (Martinez et al., 2001; Vrljicak 
et al., 2004).  
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Although BMP signaling is important, its regulation during normal kidney 
development is largely unknown. The best studied meiator is Gremlin1, an extracellular 
antagonist for BMP signaling, which inhibited the local BMP signaling and facilitating 
ureteric bud outgrowth and branching (Michos et al., 2007). In addition, the I-Smads 
were also detected in mesenchymal cells in the nephrogenic zone and at ureteric bud tips 
(Vrljicak et al., 2004). Recently, we found that Tle4 was expressed in s-shaped bodies, a 
structure derived from metanephric mesenchyme, as well as periphery mesenchyme (Cai 
et al., 2003). Tle4 has been reported to participate in the regulation of several signaling 
pathways, such as Wnt, Notch and EGF signaling (Cinnamon and Paroush, 2008). 
However, the reports of its involvement in TGF-β signaling are limited. The only data is 
from Drosophila, showing that brinker, a downstream effector of the decapentaplegic 
(dpp)/TGF-β signaling, recruited groucho and CtBP to suppress specific target genes 
(Hasson et al., 2001). Recently, Sekiya, T et al showed that the recruitment of Grg3 to 
chromatin created a closed, poorly accessible domain spanning three to four nucleosomes 
(Sekiya and Zaret, 2007). This long range repression m del may be also involved in the 
regulation of signaling pathways and help explain the various target gene profiles of a 
certain signaling pathway in different cell types. In this chapter, we reported that, instead 
of repressing the effects of BMP7 on its reporter vctor, Tle4 overexpression strongly 
activated BMP7 reporter. Similarly, Tle4 also enhanced and sustained the activation of 
endogenous Id1gene induced by BMP7. The effects of Tle4 on BMP7 signaling was not 
through modulating the phosphorylation status of Smad1, 5 and 8, but repressing Smad7 




Materials and Methods 
Reporter Molecular Construction 
The forward and reverse strands of BRE fragment with BamHI site at the 5’-end were 
synthesized by Invitrogen. 10µM of each strand was added to 5X ligase buffer 
(Invitrogen), heated to 95oC for 1 min and then cooled down to room temperature fo  
annealing. pRS4-EGFP reporter was digested by BamHI (NEB) for 3 hours and purified 
by QIAquick gel extraction kit (Qiagen). The BRE fragment was ligated with pRS4-
EGFP reporter with the ligation kit (Invitrogen) at 16oC overnight. The ligation product 
was transformed into competent DH5α E.coli (Invitrogen) followed the manufacture 
instruction and cultured on LB (EMD) plates containing 50µg/mL ampicillin (Roche). 
Plasmid DNA was mini-prepared with QIAprep Spin MiniPrep Kit (Qiagen) and 
examined by PstI digestion (NEB). The positive clones were sent to UM sequencing core 
to check the insertion orientation. To cut off the Pax2 binding sites from Pax2 and BMP 
double reporter vector, the vector was digested by HindIII and EcoRV (NEB) overnight, 
blunted by DNA polymerase I, Large (klenow) Fragment (NEB) and re-ligated with the 
ligation kit. BRE fragment sense: 5’-GATCCGCGGCGCCAGCCTGACAGCCCGT 
CCTGGCGTCTAACGGTCTGAGCTAGCG-3’; reverse: 5’-GATCCGCTAGCTCA 
GACCGTTAGACGCCAGGACGGGCTGTCAGGCTGGCGCCGCG-3’.  
Cell Culture 
293 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco) 
with 10% Fetal Bovine Serum (FBS), and Penicillin Streptomycin (PS, Gibco). 
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Immortalized renal epithelial cells (TKPTS) were a kind gift from Dr. Bello-Reuss. Cells 
were cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-
12, Gibco) with 2% FBS, 1X Insulin-Transferring-Ethanolamine-Selenium (ITES, Lonza) 
and PS. UltraMDCK serum free medium (Lonza) was used when serum starvation was 
necessary.   
To test the effect of Pax2, Tle4 or BMP7 on reporter v ctors, 293 cells were 
culture on 6 well plates with low serum medium (LSM, DMEM+0.5% FBS+1X Insulin-
Transferring-Selenium (ITS, Gibco)) and transfected with 0.5µg reporter vectors and 
0.5~1 µg Pax2, Tle4 expressing vector or SHS (sonicated herring sperm) DNA as control, 
using Fugene6 (Roche). Cells were harvest 48 hours after transfection for analysis. To 
test the effect of Smad7 on BMP reporters, cells were transfected with 0.5µg pRS4-
BRE4+-EGFP reporter vector, 0.5µg Tle4 expressing vector, and 0.5µg Smad7 
expressing vector or SHS DNA control. 100ng/mL BMP7 (R&D systems) was added 24 
hour after transfection for another 24 hours. For 1 hour pulse experiment, transfected 
cells were treated with 100ng/mL BMP7 for 1h, and then washed with PBS once and 
cultured in new LSM for another 23 hours.  
To collect the conditional medium, 293 cells were cultured on 100 mm dishes and 
transfected with 5 µg of GFP or Tl4 expressing vector, using Fugene6. 48 hours after 
transfection, culture medium from each plate was colle ted and centrifuged at 4000 rpm 





Western blot analysis 
Cells were directly lysed in 2X SDS buffer (4% sodium dodecyl sulfate, 20% 
glycerol, 0.2M dithiothreitol, 125 mM Tris, pH 6.8) and boiled at 94°C. Samples were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to PVDF membranes and immunoblotted with antibodies as indicated. Rabbit 
anti-phosphorylated Smad1/5/8 is from Cell Signaling.  Mouse anti-flag and mouse anti β-
tubulin are from Sigma-Aldrich.  Mouse anti-EGFP, mouse anti-Smad1 and rabbit anti-
Tle4 are from Santa Cruz Biotech. Rabbit anti-Pax2 is self-made.  HRP-linked secondary 
antibodies and ECL reagent are from GE healthcare.  
RNA reverse-transcription and real-time PCR  
Total RNA was extracted from 293 cells with different treatment using TRIzol 
RNA isolation system (Invitrogen). 2-3 µg total RNA was reverse-transcribed into 
complementary DNA with SuperScript First-Strand Kit ( nvitrogen).  The cDNA 
products were diluted 5 times and amplified with the iTaq Sybr green master mix (Bio-
Rad) in a Prism 7500 (Applied Biosystems).  Primers pairs for PCR are as follows: 
Id1 5’-CTGCCTGCCCTGCTGGAC-3’, 5’- TCTCGCCGTTGAGGGTGC-3’; 
Tle4 5’-TACCCCTACTCCACGAACT-3’, 5’-TCTCCGTTCATTCCAGCA-3’; Smad4 
5’-CACTACGAACGAGTTGTATCAC-3’, 5’-CCTTCAGTGGACAACGATG-3’; 
Smad7 5’-ATCACCTTAGCCGACTCTG-3, 5’-CAGTAGAGCCTCCCCACTC-3’; 





Luciferase assays  
293 cells were seeded on 12 well plates and cultured in LSM.  BRE-luc reporter 
vector was transfected (1 µg/well) together with SHS or Tle4 expressing vector (1 µg/well) 
into the cells in triplicate. Medium containing 100ng/mL BMP7, or GFP or Tle4 
conditional medium was added 24 hours after transfection and kept for another 24 hours.  
Cells were lysed with dual luciferase assay kit (Promega) and results were read.   
shRNA mediated Gene knocking-down   
Packed Smad4 37196 or 37199 shRNA lentivirus was used to knockdown in 
PRECs.  Cells were seeded on 6 well plates for 24 hours. Lentivirus was added with 8 
µg/mL polybrene and kept overnight. Puromycin was added and kept for consistent 
selection. For the BMP reporter test in Smad4 knockd wn cells, cells were seeded on 12 
well plate and cultured for 24 hours. 1.5 µg of DNA, containing 0.5 µg of pRS4-BRE4+-
EGFP reporter and 1µg of Tle4 expressing vector or SHS DNA control was transfected 
using Fugene6. 48 hours later, cells were lysed in 2XSDS loading buffer and analyzed by 
western blotting.  
Results 
Molecular Construction of Pax2 and BMP7 double reporter vector 
Considering the long range repression effect of Gro/Tle proteins, to study the 
function of Tle4 in BMP signaling, we decided to make a new BMP reporter system, 
which could recruit Tle4 near the BMP response elemnt (BRE). Because Tle4 has no 
DNA binding domain, we choose to use Pax2 as the “bridge” factor, since it has been 
well documented that Tle4 bound to Pax2, 5 and 8 through the conserved octapeptide 
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(Eberhard et al., 2000; Linderson et al., 2004; Patel et al., 2012). First, we synthesized a 
50 bp BRE fragment flanked with a BamH1 site. It was defined from Id1 promoter, 
containing two Smad binding element (SBE) and GC rich egion (Korchynskyi and ten 
Dijke, 2002) (Fig. 4-1A). Then, we inserted this DNA fragment into a Pax2 reporter 
vector (Patel et al., 2007) at the BamHI site betwen the Pax2 binding sites and TK 
promoter. Because the molecular construction was based on a single restriction enzyme, 
multiple BRE fragments could be inserted into one vector at different orientations (Fig. 4-
1B). Here, for convenience, we defined the vector as “+”, when SBE is upstream of GC 
rich region, and “-” when SBE is downstream of GC rich region. Usually, we got the 
double reporter vectors with 4 or 6 copies of BRE fragments. No matter how many copies 
the reporter vectors had, they all responded to BMP7 treatment or Pax2 overexpression 
when transiently transfected into 293 cells (Fig. 4-1C, D).  
Tle4 activated transient transfected BMP7 reporter independent of Pax2 
As previous studies stated, Tle4 abolished the transactivation ability of Pax2 
through inhibiting its phosphorylation by JNK signali g and recruiting other corepressors 
(Cai et al., 2003; Hasson et al., 2001; Patel et al., 2012; Yao et al., 2001). However, to 
our surprise, Pax2 and Tle4 co-transfection or Tle4 transfection alone strongly activated 
the Pax2 and BMP7 double reporter (Fig. 4-2A). Since Tle4 alone could activate the 
reporter, we doubted whether Pax2 binding sites were n cessary. Deletion of the Pax2 
binding sites from either EGFP or firefly luciferase reporter did not affect its activation 
by Tle4 (Fig. 4-2B, C). Furthermore, the condition medium collected from Tle4 
transfected cells failed to activate the BMP7 reporter, suggesting that this activation was 
not in a paracrine manner. Both the basal EGFP expression level and the strength of its 
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activation by Tle4 were dependent on the copy numbers of BRE fragments and the 
amount of Tle4 proteins, but regardless of the orientation of the inserted BRE fragments. 
The Tle4 dependent BMP7 reporter activation could be achieved in both human derived 
293 cells and mouse derived TKPTS, indicating that it may utilize a universal mechanism 
(Fig. 4-2D, E).  
Tle4 enhanced and sustained BMP7 mediated endogenous Id1 expression 
Since the response elements of the BRE reporter vector were isolated from Id1 
gene, we then asked whether Tle4 could activate endogenous Id1 gene. Unfortunately, 
overexpression of Tle4 only slightly increased Id1 expression (usually around 1.5 fold) 
(Fig. 4-3A). However, the presence of Tle4 significantly enhanced the effect of BMP7 in 
activating Id1 gene (Fig. 4-3B). Similarly, overexpression of Tle4 also enhanced the 
induction of genome integrated pRS4-BRE4+-EGFP report r in at least 2 independent 
clones upon BMP7 treatment (Fig. 4-3C). It has been shown that BMP7 signaling was 
required for sustained Id1 mRNA expression in pulmonary artery smooth muscle cells 
(Yu et al., 2008a). Next we checked whether Tle4 was able to prolong Id1 upregulation 
induced by BMP7 in 293 cells. After cells were treaed with BMP7 for 1 hour and then 
cultured with new fresh medium for another 24 hours, the expression of Id1 returned to 
the normal level. However, in the presence of Tle4, the expression level of Id1 remained 
at the activated state for another 24 hours, after th  1h exposure of BMP7 (Fig. 4-3D). 
Taken these together, although Tle4 alone did not alter Id1 expression much, it enhanced 
and sustained BMP7 induced endogenous Id1 expression.  
BMP7 did not affect endogenous Tle4 expression 
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Considering the robust induction of Id1 expression by BMP7, we then asked 
whether Tle4 is required for the BMP7 signaling. To our surprised, the endogenous Tle4 
protein level was low in 293 cells. Although, BMP7 may slightly increase the 
transcription of Tle4 over time, there was no detectable increasing of Tle4 protein upon 
BMP7 treatment (Fig. 4-4A, B). So, these data suggested that BMP7 might not require 
high level of Tle4 to induce target gene expression in these cells.  
Tle4 activate BMP reporter vector through mediating Smad proteins 
Next, we addressed the potential mechanisms utilized by Tle4 proteins to 
upregulate BMP reporter vector. Since the Smad proteins are the main mediators for 
BMP signaling, we first check whether Tle4 affect the phosphorylation of R-Smads. 
From Figure 4-5A, we could see that overexpression of Tle4 neither induced the 
phosphorylation of Smad1, 5 and 8, nor increased thir response to BMP7 signaling. In 
the BMP7 one hour pulse experiment, Tle4 also failed to maintain the phosphorylated 
status of Smad1, 5 and 8 after BMP7 ligands were withdrawn. However, in these 
experiments, we found that there existed a basal activity of BMP signaling, indicated by 
consistent low level of phosphorylated Smad1, 5 and 8. Considering the general function 
of Gro/Tle family as a corepressor, we doubted whether overexpression of Tle4 blocked 
the expression of BMP inhibitor(s). Thus Tle4 mediated activation of BMP reporter may 
be due to increase the efficiency of basal active Smads on the reporter. Because R-Smad 
proteins usually interacted with Smad4 to regulate gene expression (Massague, 1998), we 
used shRNA to knockdown the expression of Smad4. Two different shRNA lentivirus, 
37196 and 37199 knocked Smad4 down by 70% separately (Fig 4-5B). In Smd4 
knockdown cells, the response of BMP reporter to Tle4 was reduced, although it was still 
117 
 
strong. Also, Smad4 knockdown slightly reduced the basal level of phosphorylated 
Smad1, 5 and 8, but the total Smad1 amount was not affected (Fig 4-5C). Thus, the 
Smad4 activity was at least partially responsible for the Tle4 mediated BMP reporter 
activation. Smad7 was a common inhibitor for TGF-β and BMP signaling (Hayashi et al., 
1997; Nakao et al., 1997). We found that Tle4 inhibited endogenous Smad7 expression 
(Fig. 4-5D). More importantly, overexpression of Smad7 reduced the basal expression 
level of BMP reporter vector and totally abolished the activation effect of Tle4 (Fig. 4-
5E). Taken this together, we concluded that Tle4 did not affect phosphorylation of Smad1, 
5 and 8, but activated the BMP reporter vector through enhancing basal BMP signaling 
pathway by inhibiting Smad7 expression.  
Discussion 
BMP signaling pathway is important during normal development and diseases. 
Gro/Tle family proteins are common corepressors, which are involved in various 
signaling pathways. For example, Tle proteins competed with β-catenin to interact with 
Tcf/Lef, thus interfering canonical Wnt signaling (Daniels and Weis, 2005). However, 
the functions of Gro/Tle proteins in TGF-β signaling are largely unknown. Up to now, it 
was only reported that Dpp, the TGF-β homolog in Drosophila, induced the expression of 
Brinker, which recruited Groucho and CtBP to repress other Dpp target genes, thus 
confining the function zone of Dpp signaling (Hasson et al., 2001; Zhang et al., 2001). In 
this chapter, we discuss the potential function of Tle4 to enhance BMP signaling by 




First, in our Smad4 knockdown experiment, the endogen us Smad4 expression 
was knocked down by 70%, but Tle4 still strongly activated the BMP reporter, even 
though its effect was reduced. Also, there still was  detectable basal level of 
phosphorylated Smad1, 5 and 8. Since previous studies showed that Smad4 was 
dispensable for TGF-β signaling (Descargues et al., 2008; He et al., 2006), to further 
address the question whether Tle4 mediated induction of BMP reporter was through 
enhancing the basal BMP activity, two more experiments are needed: (1) checking the 
effect of Tle4 on the BMP reporter in the presence of BMP inhibitors, such as Noggin, a 
secreted protein preventing BMP ligand-receptor interaction, or dorsomorphin, a small 
molecule blocking BMP receptors (Yu et al., 2008b); (2) check the effect of Tle4 on 
modified BMP reporter without Smad binding element.  
Second, Smad7 inhibits BMP signaling through interfering the binding of R-
Smads to Smad4 or type I receptor (Hayashi et al., 1997). Our data suggested that Tle4 
activated BMP reporter by inhibiting Smad7 expression. More experiments are required 
to support this idea. First, a workable Smad7 antibody is needed to show the decreased 
protein level of Smad7 upon Tle4 overexpression. Then, we could check whether Smad7 
knockdown by lentivirus would mimic Tle4 overexpression to activate BMP reporter. 
Since Tle4 robustly activated the BMP reporter and Smad7 strongly inhibited this effect, 
if Tle4 overexpression does not greatly reduce Smad7 at protein level, a second blocking 
point may exist. Tle4 may prevent Smad7 from interfering with the complex formation 
between R-Smads and Smad4. Thus, a co-immunoprecipitation (co-IP) experiment is 
needed to check the interaction between R-Smads and Smad4 in the presence of Tle4 or 
not. Furthermore, the balance between acetylation and ubiquitination was important to 
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control the stability of Smad7 (Gronroos et al., 200 ; Simonsson et al., 2005). Since Tle4 
was able to interact histone deacetylase 1(HDAC1) (Choi et al., 1999), it may also 
influence Smad7 degradation . 
Third, although Tle4 strongly activated BMP reporter, its effect on the expression 
of endogenous Id1 gene was limited. This results from the different properties between 
transiently transfected vector and endogenous genes: (1) the regulation for reporter 
vectors was much simpler than real genes. In fact, besides Smad proteins, Id1 promoter 
contains binding sites for several other transcriptional factors, such as YY1, Sp1 and 
ATF3 (Kang et al., 2003; Korchynskyi and ten Dijke, 2002). It is hard to imagine that 
Tle4 could control all of these factors at the same ti e on its own; (2) the expression of 
endogenous genes is usually affected by the chromatin structure, while transiently 
transfected vectors are more accessible to activators. This idea was supported by the 
stable transfected cell line with BMP reporters, whose response to Tle4 overexpression is 
more like endogenous Id1 genes than transiently transfected reporters. Two potential 
mechanisms may lead to the Tle4 mediated enhanced or sustained expression of 
endogenous Id1induced by BMP7. First, just like the situation of BMP reporter vector, 
the effect of Tle4 on Id1 gene is through repressing Smad7, thus the enhanced and 
sustained Id1 expression is dependent on R-Smads. To demonstrate this idea, an 
experiment to check the Tle4 effect on BMP7 induced Id1 gene expression in the 
presence of Smad7 overexpression is necessary. We have already tried to check the 
combination effect of Tle4 overexpression and BMP7 administration on Smad7 
expression. However, the results were not consistent among repeats. This may result from 
the technique problem. Since we cannot guarantee th transfection efficiency is 100%, 
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the Smad7 expression change we saw in RT-PCR may be the net effect of BMP7 
mediated upregulation in some of cells and Tle4 mediat  downregulation in other cells. 
The variants of transfection efficiency over repeats may directly influence the results. So, 
the plan to overexpress Smad7 should be a better choice, because it is easier to guarantee 
the co-transfection of Smad7 and Tle4. Also, a chromatin immunoprecipitation (ChIP) 
assay with Smad4 or R-Smads at Id1 promoter will provide more evidence to prove 
whether the enhanced and sustained Id1 expression is dependent on R-Smads. Although, 
it is widely believed that Gro/Tle family proteins are corepressors, a recent study showed 
that Tle3 was also present at the promoters of activated genes (Villanueva et al., 2011). 
So it is possible that Tle4 may function as an adaptor and also directly mediate Id1 gene 
expression. Because Tle4 itself has no DNA binding domain, it requires other 
transcriptional factors and a more accessible chromatin environment, this can explain 
why Tle4 alone only slightly increased Id1 expression. To demonstrate this idea, a ChIP 
assay with Tle4 at Id1 promoter is necessary. 
Finally, because the endogenous Tle4 level is low in 293 cells, it may not be a 
good tool to address the biological importance of Tle4 in BMP signaling. The 
metanepheric mesenchymal cells and its derived epith lia in s-shape body have relative 
high Tle4 expression (Cai et al., 2003), they may be a better tool for further studies. We 
could try to isolate those cells from E15.5 embryos, knockdown endogenous Tle4 
expression and test its response to BMP7 for proliferation and cell survival (Dudley et al., 
1999).  
In summary, studying the regulation of BMP7 signalig is critical for us to 
completely understand its function in renal development. The present data showed that 
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Tle4 play an important role in regulating BMP7 mediated Id1 expression. As shown in 
Figure 4-6, Tle4 may enhance BMP effects through modulating Smad7. This could be 
achieved by downregulating Smad7 expression, preventing it from blocking the complex 
formation of R-Smad and Smad4, or influencing its sability. A more aggressive 
hypothesis is that Tle4, instead of acting like a corepressor, can directly mediate gene 
activation. Although more experiments are required to prove these potential mechanisms, 
















Figure 4-1. Molecular Construction of Pax2 and BMP7 double reporter vector. A) 
Schematic of molecular construction of the double repo ter vector. BMP response 
fragment was inserted into the BamHI site between Pax2 binding element (Pax2 BE) and 
TK promoter. Insertion with SBE upstream of GC rich region was defined as (+), and 
reversed insertion was defined as (-). B) DNA agarose electrophoresis showed the 
restriction endonuclease digestion of double reporter vector with different insertion 
copies. Vectors were cut by PstI and for every insertion copy, there would be a 50 bp 
shift in the electrophoresis. Clone #4 was the negative control for empty vector. C) 
Western blots for EGFP showed the response of double reporter with different insertion 
copies and orientation to BMP7 treatment for 24 hours. D) Western blots for EGFP 
showed the response of double reporter with 2 insertion copies and (+) direction to Pax2 











Figure 4-2. Tle4 overexpression activated transiently transfected BMP reporter. A) 
Western blots showed the response of cells transiently transfected with Pax2 reporter 
(RS4) or double reporter with four insertion copies in (+) direction to overexpression of 
Pax2 and Tle4. B) The same experiment as in A) but with BMP reporter without Pax2 
binding sites. C) Luciferase assay was used to measur  the response of BMP reporter to 
Tle4 overexpression or conditional medium (CM) collected from cells overexpressing 
Tle4. BMP7 treatment was used as positive control and CM collected from cells 
overexpressing GFP was used as negative control. D) Western blots showed the response 
of cells transiently transfected with the double reporter of different copy numbers or 
orientation to Tle4 overexpression in 293 cells andTKPTS, an immortalized renal 
epithelial cell line. E) Western blots showed the response of cells transiently transfected 
with BRE4+ double reporter to increasing doses of overexpressed Tle4. All samples were 







Figure 4-3. Tle4 enhanced and sustained BMP7 mediated endogenous Id1 expression. 
A) upper: the response of endogenous Id1 gene to different amount of overexpressed 
Tle4 proteins was measured by qRT-PCR; lower: increasing amount of Tl4 expressing 
vector was transiently transfected into 293 cells to achieve different amount of Tle4 
expression level, as indicated by western blots. B) upper: the response of endogenous Id1 
gene to Tle4 overexpression and/or BMP7 treatment was measured by qRT-PCR; lower: 
equal amount of Tle4 was expressed with or without BMP7 treatment, as indicated by 
western blots. C) Western blots showed the response f BRE4+ double reporter stable 
transfected cell lines (#6 and #27) to Tle4 overexpssion and/or BMP7 treatment. D) Id1 
expression was measured by qRT-PCR upon Tle4 overexpression, BMP7 treatment for 
24 hours, or BMP7 1 hour pulse in the presence or absence of Tle4 overexpression. All 
samples were done in triplicate with error bars representing one standard deviation (SD) 









Figure 4-4. BMP7 did not affect endogenous Tle4 expression. A) qRT-PCR showed 
Tle4 RNA levels in 293 cells cultured with BMP7 for the indicated time in hours. B) 
Western blot showed Tle4 protein levels in 293 cells cultured with BMP7 for the 
indicated time in hours. All samples were done in triplicate with error bars representing 
















Figure 4-5. Tle4 activate BMP reporter vector through mediating Smad proteins. A) 
Western blots showed the P-Smad1/5/8 level upon Tle overexpression and/or BMP7 
treatment for 24 hours or BMP7 1 hour pulse in the presence or absence of Tle4 
overexpression. B) qRT-PCR showed Smad4 RNA levels after culture with shRNA 
#37196, #37199 or a scrambled control. C) Western blots showed the response of BRE4+ 
double reporter to Tle4 overexpression in Smad4 knoc d wn cells by shRNA #37196 
and #37199 or scrambled control cells. P-Smad1/5/8 and total Smad1 were also probed. 
D) qRT-PCR was used to measure the endogenous Smad7 RNA level upon Tle4 
overexpression. E) Western blots showed the response f BRE4+ double reporter to Tle4 
overexpression and/or Smad7 overexpression. P-Smad1/5/8 was also probed. All samples 










Figure 4-6. Schematic diagram showing the regulation of Tle4 in BMP7 signaling. 
Arrows indicates the promotion, “┬” means the inhibition and “?” means uncertain. Ac,
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Since the discovery of TGF-β1 in 1983, more than 30 different TGF-β 
superfamily ligands have been found in the human geome. Accumulated evidence 
shows that the TGF-β superfamily is critical for early embryogenesis, a well as the 
formation of nearly all organs. The TGF-β superfamily is also widely involved in various 
diseases, such as organ fibrosis and tumor metastasis. Considering its crucial role in 
development and diseases, it is important to carefully dissect the TGF-β superfamily 
signaling pathway to understand the mechanisms that it utilizes to regulate target gene 
expression both outside and inside of cells. In this t esis, we discovered that TGF-β 
activated JNK signaling through inducing Wnt11 expression and Wnt11 was necessary to 
upregulate mesenchymal marker genes in renal epithelial c lls. These results not only 
revealed the direct targets of the TGF-β signaling pathway, but also, for the first time, 
integrated TGF-β, Wnt and JNK signaling within the context of the epithelial-
mesenchymal transition. 
 In the UUO models, the overexpression of the KCP protein, a secreted TGF-β 
inhibitor, reduced the upregulation of Wnt11 in the injured kidney. Furthermore, the 
overexpressed KCP proteins disturbed the balance of TGF-β and BMP signaling during 
renal fibrosis and attenuated the upregulation of mesenchymal genes. This suggested that 
the extracellular regulation of TGF-β and BMP signaling pathways is critical for their 
physiological functions during disease progression. Besides the extracellular mediators, 
the BMP signaling is also regulated within the cells. As shown in my thesis, Tle4 can 
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enhance and sustain endogenous Id1 gene expression, pr bably through repressing 
inhibitory Smad7. This modification of BMP signaling by Tle4 is important for at least 
two reasons. First, some cellular physiological effects of BMP signaling are dependent on 
the activation of Id genes. For example, Ids are part of the machinery that mediates the 
regulation of hair cell and satellite cell differentiation exerted by BMPs (Kamaid et al., 
2010; Ono et al., 2011). Second, since Tle4 amplifies the BMP signaling within cells, its 
specific expression pattern can mimic the effects of BMP gradients, thus causing various 
responses of different types of cells to the same BMP signaling. Taken together, my 
thesis systematically studied the mechanisms and regulations of TGF-β and BMP 
signaling in mediating target gene expression both in vitro and in vivo, thus deepening 
our understanding of TGF-β superfamily (Fig. 5-1). In the following paragraphs, I will 
further discuss the implication of my work by chapters. 
TGF-β signaling is well characterized for its pro-fibrogenic effects in kidney 
diseases (Liu, 2010). In vitro, TGF-β promotes the transition of epithelial cells to 
fibroblasts-like cells by downregulating epithelial markers, such as E-cadherin, and 
activating mesenchymal genes, such as Snail1, Pai1 and Zeb1 (Yang and Liu, 2001). 
Although the existence of EMT in vivo is controversial (Kriz et al., 2011), enforced 
expression of mesenchymal genes, such as Snail1, in epithelial cells induced renal 
fibrosis in mice (Boutet et al., 2006). In human, a dr stic accumulation of Snail1 was 
seen in the nuclei from tubular epithelial cells in k dney samples with multiple myeloma 
cast nephropathy, a disease characterized by a rapid progression toward fibrosis. 
However, such accumulation of Snail1 was not found i  kidney samples with an 
idiopathic nephritic syndrome, a syndrome unassociated with renal fibrosis (Hertig et al., 
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2011). These data suggest that the upregulation of mesenchymal genes in epithelial cells 
can be a major factor in the initiation and progression of renal fibrosis. 
In the first part of this thesis, we found that Wnt11, a ligand belonged to Wnt 
signaling family, enhanced TGF-β mediated mesenchymal gene activation in renal 
epithelial cells. Furthermore, Wnt11 was directly regulated by Smad3 proteins, but not 
Smad2. This was consistent with the previous results showing that Smad2 functioned as a 
protector against Smad3 in renal fibrosis (Meng et al., 2010). In fact, although Smad2 and 
3 share similar structure and are both activated by TGF-βs, their biological functions are 
not the same. Compared to the early embryonic lethality of Smad2 mutants (Waldrip et 
al., 1998), the phenotypes of Smad3 mutants were much less severe and could survive for 
1-8 months after birth (Yang et al., 1999). Detailed studies showed the different target 
gene profiles of Smad2 and 3 in human and rat epithlial cell line (Chung et al., 2010; 
Phanish et al., 2006). Recently, Smad4 was shown to be important for the progression of 
renal fibrosis, as well as for Smad3 mediated Collagen I expression (Meng et al., 2012). 
Since both Smad2 and 3 can interact with Smad4, but Smad2 lacks the DNA binding 
domain, it is possible that Smad2 counteracts Smad3 by competing for the Smad4 
interaction. Thus, it will be interesting to test whether Smad3 proteins interact with 
Smad4 strongly in the absence of Smad2 and whether a modulated Smad2 protein with 
DNA binding domain may facilitate Collagen I expression upon TGF-β treatment. With 
respect to the Wnt11, because it was regulated only by Smad3, but not Smad2, it may 
serve as a biomarker to distinguish the Smad2 and Smad3 mediated pathways.  
The modulation of Wnt11 significantly affected TGF-β mediated upregulation of 
mesenchymal genes without influencing Smad proteins, suggesting that once activated, 
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Wnt11 functioned independently of TGF-β signaling. However, the sustain activation of 
Wnt11 during EMT still required TGF-β signaling, since a selective inhibitor of TGF-β 
type I receptor, SB431542 strongly blocked the Wnt11 expression, even after Wnt11 has 
already been activated by TGF-β1 (data not shown). This further demonstrated the central 
status of TGF-β signaling in driving EMT.  
It has been reported that TGF-β could stimulate JNK signaling, though the 
mechanisms were unknown (Mao et al., 2011; Shin et al., 2011). Now, our data 
demonstrated that the activation of JNK signaling i TGF-β mediated EMT was at least 
partially through Wnt11. Instead of activating canonical/β-catenin signaling, Wnt11 
mediated the expression of mesenchymal genes throug non-canonical/JNK signaling. 
This discovery also broadened the understanding of the crosstalk between TGF-β and 
Wnt signaling. Previously, the limited number of studies addressing the crosstalk of TGF-
β and Wnt signaling pathways converged on β-catenin, as TGF-β could stabilize β-
catenin by inhibiting its GSK3β-dependent degradation through p38 MAPK and Akt 
(Hwang et al., 2009; Liu, 2010; Masszi et al., 2004).  Also β-catenin could physically 
interact with Smad proteins to regulate target gene expression (Kim et al., 2009; Zhang et 
al., 2010; Zhou et al., 2012). Our data is the first direct evidence showing the crosstalk 
between TGF-β and non-canonical Wnt signaling. Indeed, we found no evidence that 
canonical Wnt pathway was activated by TGF-β. 
The studies on the regulation of TGF-β and BMP signaling are equally important, 
as these regulations control the strength of the signaling and specify the final cellular 
responses. KCP is a secreted protein containing 18 CR domains. It possesses a dual role 
in enhancing BMP signaling and inhibiting TGF-β signaling (Lin et al., 2005; Lin et al., 
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2006). In the second part of the thesis, we examined whether modulating the balance of 
TGF-β and BMP7 signaling by overexpressing KCP in transge ic mice affected the 
progression of kidney injury in UUO models. We found that the upregulation of 
mesenchymal marker genes was attenuated by KCP overexpr ssion in the UUO mouse 
model. This is consistent with the retarded progression of renal fibrosis in KCP 
transgenic mice, as demonstrated by less α-SMA and Collagen V region (data not shown). 
What is more important, we found that upregulation of Wnt11 was also reduced in KCP 
transgenic mice. This further demonstrated that Wnt11 was a target of TGF-β signaling 
and was closely associated with renal fibrosis. Although our in vitro cell model indicated 
that Wnt11 promoted EMT, the current mouse model cannot distinguish whether Wnt11 
is only a biomarker for renal fibrosis or a mediator f r this process. Since the Wnt11 
mutant mice died by 2 days postpartum, because of abnormal heart development 
(Majumdar et al., 2003), Wnt11 conditional knockout mice are needed to further study its 
function during renal fibrosis. In this case, Pepck promoter can be used to drive the 
expression of Cre recombinase, since it is very active in adult renal proximal tubular 
epithelia (Short et al., 1992). An available alternate plan for Wnt11 conditional knockout 
mice is to use Fzd4-/- mice. Fzd4-/- mice were viable and showed similar renal hypoplasia 
as Wnt11-/- mice (Ye et al., 2011), suggesting that Wnt11 may function through Fzd4. 
However, the potential problem for using this Fzd4-/- mouse model is the receptor 
redundancy, since it has been reported that Wnt11 can also transduce its signaling 
through Fzd7 or Fzd8 (Yamanaka and Nishida, 2007; Ye et al., 2011), both of which are 
expressed during renal fibrosis (He et al., 2009).  
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Under normal condition, most BMP type II receptors a e localized in epithelial 
cells (Bosukonda et al., 2000), as are TGF-β type I receptors in the UUO model (Yang 
and Liu, 2001). These data suggested that renal epithelial cells are the main participants 
in responding to TGF-β/BMP signals. At early time (7 days), the differencs of activation 
of Wnt11, Pai1 and Snail1, between KCP and wildtype mice were not significant, 
indicating that the effects of epithelial cells in initiating renal fibrosis may be limited. 
However, by 14 days, the upregulation of all the examined mesenchymal genes and 
myofibroblast markers, was reduced in KCP transgenic mice, indicating that epithelial 
cells play a crucial role in promoting fibrosis. One defect for our current model is that the 
expression of transgenic KCP proteins decreased along with progression of renal fibrosis. 
This may result from the increased apoptosis of epith lial cells or the silencing of Pepck 
promoter during the injury. To better address the function of KCP in renal fibrosis, a new 
KCP overexpression model may be generated. In this model, KCP gene may be knocked 
in at Rosa26R site with a 5’ upstream stop signal flanked by loxp sites. If this mouse was 
bred to the mouse with Cre expression driven by Pepck promoter, KCP will also 
overexpress in all renal proximal tubular cells. The advantage for this model is that we 
may avoid the silence of Pepck promoter and maintain KCP expression during renal 
fibrosis.  
Considering the secreted property of the KCP protein, it may affect neighboring 
cells as well. Previous results revealed that BMP7 could induce adult renal fibroblasts to 
differentiate to epithelial cells (Zeisberg et al., 2005). Thus, the overexpressed KCP may 
enhance the BMP signaling to limit the number of fibroblasts during renal fibrosis. 
Another potential target for BMP signaling is interstitial stromal cells, which are 
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quiescent undifferentiated mesenchymal cells (Dressler, 2006). Since BMP signaling is 
important to maintain the pluripotency of stem cells (Varga and Wrana, 2005), during 
renal fibrosis, the decreasing BMP7 signaling may contribute to the differentiation of 
these stromal cells into fibroblasts. Meanwhile, the destruction of the stem cell pool may 
also reduce the recovery ability of the kidneys from the injuries. Thus, it will be 
interesting to test whether KCP overexpression can improve the renal recovery in acute 
renal diseases, such as acute tubular necrosis (ATN) model induced by injection of folic 
acid (Lin et al., 2005).  
Besides the extracellular regulation, BMP signaling is also modulated within cells. 
In the third part of the thesis, we discussed how BMP signaling is regulated by Gro/Tle 
proteins. Gro/Tle family proteins are common corepressors. Up to now, the only reported 
relationship between TGF-β signaling and Tle proteins was that Dpp, the TGF-β homolog 
in Drosophila, induced the expression of Brinker, which recruited Groucho and CtBP to 
repress other Dpp target genes, thus confining the functional zone of Dpp signaling 
(Hasson et al., 2001; Zhang et al., 2001). Since Gro/Tle proteins could mediate a long 
range suppression via compacting chromatin (Sekiya and Zaret, 2007), our original idea 
was to test whether the recruitment of Tle4 to DNA can influence the nearby BMP 
response elements. Thus, we constructed the Pax2 and BMP7 double reporter vector, 
using Pas2 as the bridge factor to recruit Tle4. Much to our surprise, overexpression of 
Tle4 strongly activated BMP reporter independent of Pax2, as well as enhancing and 
sustaining the BMP7 effect on endogenous Id1 gene in 293 cells. The effects of Tle4 on 
BMP7 signaling may be mediated through Smad7 proteins, since Tle4 suppressed Smad7 
transcription, while Smad7 overexpression completely abolished the effects of Tle4 on 
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BMP reporter. However, Tle4 only suppressed Smad7 transcription by ~50%, but its 
effect on the activation of BMP reporter was robust. This suggested that Tle4 may also 
influence Smad7 at the protein level. The balance between acetylation and ubiquitination 
was important to control the stability of Smad7 (Gronroos et al., 2002; Simonsson et al., 
2005). Since Tle4 was able to interact histone deacetylase 1(HDAC1) (Choi et al., 1999), 
it may help erase the acetylation marker from Smad7 to facilitate its ubiquitination and 
further degradation.  
If Tle4 mediates BMP7 signaling by repressing Smad7, the activation of BMP7 
reporter by Tle4 is actually the derepression of the basal BMP7 activity. Indeed, in 293 
cells, we detected a basal level of phosphorylated Smad1, 5 and 8. Furthermore, Smad4 
knockdown reduced the effect of Tle4 on BMP7 reporter, although the extent was limited. 
Here, using the BMP receptor inhibitor will be a better choice than Smad4 knockdown. 
Smad1, 5 and 8 themselves have DNA binding domain, thus may directly mediate gene 
transactivation (Korchynskyi and ten Dijke, 2002). In contrast, the BMP receptor 
inhibitor, such as DMH1, could specifically and efficiently block BMP signaling by 
inhibiting the phosphorylation of Smad1, 5 and 8, thus resulting in a clearer background 
(Hao et al., 2010). Since Smad7 can also block TGF-β signaling (Hayashi et al., 1997), it 
will be interesting to test whether Tle4 overexpression can activate TGF-β reporter, 3TP-
luc, as well.  
It is noticeable that Tle4 could activate BMP reporter even stronger than BMP7 
administration, suggesting that it may use other mechanism, besides repressing Smad7, to 
mediate BMP signaling. Tle4 may directly mediate activ tion of BMP reporter and 
endogenous Id1 gene, since recent study showed that Tle3 was presented at the promoters 
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of activated genes (Villanueva et al., 2011). If this is the case, it is important to determine 
which transcriptional factor binds to the BMP bindig element (SBE) and recruits Tle4. 
The first candidate will be Smad proteins. However, Smad proteins lacked the common 
interaction motif for Gro/Tle proteins, such as WRPW tetrapeptides and Engrailed 
homology 1 (Eh1) sequences (Buscarlet and Stifani, 2007). Besides the SBEs, the BMP7 
reporter also contains a GC rich region, which may be the binding site for other 
transcriptional factors. A chromatin immunoprecipitation (ChIP) assay for Tle4 will 
confirm the presence of Tle4 at the promoter region of Id1 gene.    
Although Tle4 could modulate the BMP signaling, theBMP signaling pathway 
does not affect the amount of endogenous Tle4 proteins. In fact, BMP7 did not influence 
the expression of any Tle proteins, from Tle1 to Tle3 (data not shown). Since the basal 
Tle4 protein level is low in 293 cells, it seemed that BMP signaling pathway did not 
require Tle proteins to activate target genes. Thus, to further address the biological 
importance of Tle4 in BMP signaling, the metanepheric mesenchymal cells and its 
derived epithelia may be a better tool, because they have relative high endogenous Tle4 
expression (Cai et al., 2003). It will be valuable to test whether Tle4 knockdown in those 
cells affects their response to BMP7 for proliferation and cell survival (Dudley et al., 
1999).  
Finally, although Gro/Tle proteins are important corepressors and studied in 
different types of cancers (Buscarlet and Stifani, 2007), their involvement in renal 
fibrosis is totally unknown. We even do not know whether those proteins are expressed in 
adult kidneys. However, considering the amplification effect of Gro/Tle proteins on BMP 
signaling, it is interesting to check their expression during renal fibrosis. Since the target 
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of Tle4, the Smad7 proteins, is involved in the regulation of both TGF-β and BMP 
signaling, the precise function of Tle4 in renal fibrosis may be complicated, but it may 
serve as another regulation point to balance the TGF-β and BMP signaling in vivo.  
In summary, this dissertation analyzed both the mechanisms and regulations of 
TGF-β superfamily mediated target gene expression in renal pithelia. The work provided 
further insight into the TGF-β signaling and may provide new clues for the medical 
















Figure 5-1. Schematic diagram summarizing the mechanisms and regulation of 
TGF-β superfamily mediated gene expression in this thesis. Arrows indicates the 
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